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Abstract 
DNA damage is a relatively common event in the life of cell. Based on type and location of 
DNA lesion several cellular responses are induced that enables the cell either to repair the 
damage or to activate a programmed cell senescence or death process. The precise knowledge 
of the molecular mechanisms that determine DNA damage lesion and downstream signaling 
response remains, however, elusive. 
The uPA/uPAR is a multifaceted system mediating a diverse array of extracellular and 
intracellular processes. We observed that the level of uPAR expression plays a decisive role in 
regulation of telomeric repeat binding factor 2 (TRF2) during doxorubicin-induced 
senescence. TRF2 is the main telomere-associated protein implicated in the maintenance of 
DNA structure and known to be necessary for proper telomere function. Our results 
demonstrate that uPAR controls the ubiquitin-proteasome system in vascular smooth muscle 
cells (VSMC) and regulates doxorubicin-induced TRF2 ubiquitination and proteasomal 
degradation via this mechanism.  
Using repairable DNA damage response model, we found that uPAR also involved in DNA 
damage repair mechanisms. The underlying pathways involved uPAR-mediated regulation of 
the proteasome regulatory subunit, Rpn7 and its redistribution to DNA damage foci. We 
further showed that Rpn7 nuclear translocation requires Rpn7 association with the tyrosine 
kinase c-Abl. We provide evidence that nuclear c-Abl associates with the tyrosine 
phosphatase SHP-2, which undergoes acetylation and serves for regulation of DNA repair. 
In this thesis we elucidated mechanisms underlying uPAR mediated DNA damage response 
with particular focus on DNA repair mechanism and senescence as an important consequence 
of irreparable telomeric lesion. Elucidation of the factors involved in DNA damage response 
mechanisms may lead to novel therapeutic avenues for age related disease and cancer. 
 
 
Key words: Urokinase receptor, DNA damage response, TRF2, Ubiquitin proteasome system 
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Zusammenfassung 
Der Umgang mit DNA Schädigung spielt eine große Rolle im Leben einer Zelle. Je nach Ort 
und Typ der DNA Läsion werden dabei verschiedene zelluläre Antworten induziert, die Zelle 
entweder dazu befähigen, den Schaden zu reparieren oder zur programmierten Zellseneszenz 
und Zelltod führen. Über die zugrunde liegenden molekularen Mechanismen und Signalwege 
der DNA Schädigung und der dadurch induzierten zellulären Antwort ist wenig bekannt.   
Das Urokinase-Plasminogen-Aktivator (uPA) / uPA-Rezeptor (uPAR) System reguliert eine 
Vielzahl von intra- und extrazellulären Prozessen. Wir haben herausgefunden, dass das uPAR 
Expressionslevel eine entscheidende Rolle in der Regulation des „Telomeric Repeat Binding 
Factor 2“ (TRF2) bei der Doxorubicin-induzierten Zellseneszenz spielt. TRF2 ist als 
wichtiges Telomer assoziiertes Protein maßgeblich an der Aufrechterhaltung der DNA 
Struktur beteiligt und notwendig für die regelrechte Telomer Funktion. Unsere Ergebnisse 
demonstrieren, dass uPAR das Ubiquitin-Proteasom-System in glatten Gefäßmuskelzellen 
(VSMC) kontrolliert und dadurch die Doxorubicin-induzierte TRF2 Ubiquitinierung, sowie 
dessen proteosomalen Abbau reguliert.  
Durch die Untersuchung von zellulären Antworten auf nicht letale DNA-Schädigung fanden 
wir heraus, dass die zugrundeliegenden Signalwege die uPAR-vermittelte Regulation der 
proteosomalen Untereinheit (Rpn7) und deren Rekrutierung in die Regionen der DNA 
Schädigung beinhalten. Für die nukleäre Translokation von Rpn7 wird die Assoziation mit der 
Tyrosinkinase c-Abl benötigt. Wir konnten außerdem zeigen, dass die nucleäre c-Abl mit der 
Tyrosinphosphatase SHP-2 assoziiert ist, die wiederum nach Acetylierung an der Regulation 
der DNA Reparatur beteiligt ist.  
In dieser Doktorarbeit werden die Mechanismen der uPAR-vermittelten Antwort auf DNA 
Schädigung dargestellt. Der besondere Fokus liegt dabei auf DNA Reparaturprozessen, sowie 
auf Seneszenz, als einer wichtigen Konsequenz auf irreparable Telomerläsionen. Diese Arbeit 
kann dazu beitragen, Faktoren zu identifizieren, die im Antwortmechanismus auf DNA 
Schädigung eine Rolle spielen und somit den Weg zu neuen therapeutischen Strategien gegen 
alterungsabhängige Krankheit und Krebs eröffnen.  
Schlüsselwörter: Urokinase Rezeptor, Antwort auf DNA-Schädigungen, TRF2, Ubiquitin-
Proteasom-System 
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1.1.Urokinase type plasminogen activator receptor 
The urokinase-type plasminogen activator receptor (uPAR) is a glycosyl phosphatidylinositol 
(GPI)-anchored protein involved in a variety of biological processes including fibrinolysis, 
inflammation, tissue development, extracellular matrix (ECM) remodelling during wound 
healing, atherosclerotic plaque formation, angiogenesis, tumor invasion, and metastasis. 
uPAR is part of a cell surface system that consists of the serine protease urokinase (uPA) and 
specific inhibitors  named plasminogen activator inhibitors 1 and 2 ( PAI-1, PAI-2).  
Through binding with its natural ligand uPA, uPAR regulates proteolytic activity at the cell 
surface involved in cellular responses in both physiological and pathological conditions. In 
addition to mediating proteolysis it acts as a signalling receptor that promotes cell migration, 
proliferation and adhesion [1-3]. The uPAR signalling function is independent of uPA 
proteolytic activity and in some cases does not require ligand binding [4]. 
 
1.1.2. uPAR structure 
The uPAR is a member of the lymphocyte antigen 6 family, composed of three domains: the 
amino terminal D1 domain, the linker D2 domain and carboxy-terminal D3 domain [5]. The 
domains packed together into a concave structure making a central cleft for uPA domains 
interactions [6, 7]. This keeps the entire structure of uPAR free for interaction with 
transmembrane proteins such as integrin, vitronectin, signalling receptors e.g. EGFR, GPCR, 
FPRL, PDGFR and with different modulators (Fig1) [3, 8, 9].  
uPAR binding to the cell membrane through its third domain allows the localization of cell 
surface proteolytic activity. Cleavage of the GPI anchor by phospholipases or extracellular 
proteases results in the soluble forms of uPAR (suPAR), which possesses functional activity 
[10]. Cleavage at the site of linker gives rise to the truncated form of uPAR consisting of the 
domains D2 and D3 that can be associated with membrane or shed [10-12]. Such cleavage 
affects the biological activity of uPAR in both extracellular proteolysis and cell signaling. 
uPAR is highly glycosylated at residues in all domains and glycosylation pattern of uPAR 
differs between cell types and can be changed during activation of signalling pathways [13, 
14]. It can also affect trafficking and the solubility of uPAR as well as interaction of uPAR 
with its ligand [14-16].  
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Figure 1.The structure of uPAR .a. The location of the ligand-binding sites and the GPI 
anchor. b. The three dimensional (3D) structure of uPAR, with domains coloured as in part 
[17]. 
 
1.1.3. uPAR expression 
In the physiological condition, uPAR is expressed in various tissues including lungs, kidneys, 
spleen, vessels, uterus, bladder, thymus, heart, liver, testis and others. The enhanced uPAR 
expression is observed during ECM remodeling in gestational tissues [18], during embryo 
implantation, placental development [19] and during epidermal wound healing [20].  
Stress, injury and inflammation also induce uPAR expression. It has been documented that 
uPAR expression is increased in many pathological conditions such as cancer, inflammation 
and infections. A wide variety of human cancers including solid tumours, leukaemias and 
lymphomas overexpress uPAR [21, 22] and increased level of suPAR in body fluids correlates 
with poor prognosis in cancer [21]. Systemic levels of suPAR positively correlate with 
inflammation in cardiovascular diseases, type-2-diabetes mellitus, immune system activation, 
cancer and mortality [23, 24]. 
uPAR expression is increased through many signaling pathways by activating transcription 
factors that act on the uPAR promoter. Control of uPAR transcription is mediated by 
extracellular signal-regulated kinase (ERK) through activator protein 1 (AP1), a transcription 
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factor that contributes to the mitogenic effect of Ras–ERK signalling in tumour cells [25]. 
Nuclear factor-κB (NF-κB) also activates uPAR expression, through a non-consensus NF-κB-
binding site in the uPAR promoter [26]. The expression of uPAR could be also regulated at 
the post-transcriptional level through the function of mRNA binding proteins [27]. Regulatory 
proteins that bind PLAUR mRNA encoding uPAR can affect its stability or induce mRNA 
degradation [28]. 
1.1.4. uPAR functions 
1.1.4.1. Proteolytic functions 
uPAR regulates extracellular proteolytic cascade of the plasminogen activation system (PAS), 
which is considered as an important regulator of ECM proteolysis. uPAR binds the inactive 
zymogen form proenzyme of uPA (pro-uPA), which is then converted to active uPA on cell 
membrane or in solution. Activated uPA in turn is capable to generate plasmin from 
plasminogen thus degrading intravascular fibrin and ECM. Generated plasmin triggers a 
cascade of matrix metalloproteinases (MMP) activation that additionally contributing to the 
ECM digestion. uPAR mediated ECM degradation is involved in diverse cellular process 
including proliferation, migration and adhesion. Further activities of plasmin may result in 
increased level of active fibroblast growth factor (bFGF) and vascular endothelial growth 
factor (VEGF) as a consequence of ECM degradation, as well as the direct activation of 
transforming growth factor-beta (TGF-β) [29]. Therefore, the role of uPAR-mediated 
extracellular proteolysis extends beyond ECM degradation to the control of cell growth and 
differentiation through growth factor activation or their release from ECM (Fig 2). 
1.1.4.2. Non-proteolytic functions 
In addition to regulation of extracellular proteolysis, many biological activities of uPAR are 
independent of the uPA proteolytic activity and can even occur in the absence of uPA. These 
functions are largely related to the regulation of cell functional behaviour, interactions 
between the cells and the surrounding ECM. It is well documented that uPAR in spite of 
lacking the transmembrane and cytoplasmic domains possesses ability for intracellular 
signaling through its interaction with different transmembrane proteins. By these interactions 
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uPAR is able to transduce signals and mediate diverse intracellular signalling involved in cell 
adhesion, migration and proliferation.  
 
 
 
 
Fig 2.  Effect of uPAR proteolytic activity on matrix degradation and growth factor 
activation. uPAR binds inactive pro-uPA, which is then converted to active uPA leading to 
conversion of the inactive zymogen plasminogen to active plasmin. This cascade mediates 
degradation of fibrin and ECM or activation of latent growth factors. Figure adapted and 
modified from Alfani D., et al.[30] 
 
uPAR interacts with the matrix protein vitronectin via the somatomedin B domain (SMB) of 
vitronectin [31, 32]. In addition to such a direct interaction with matrix proteins, uPAR 
interacts with integrin adhesion molecules [33]. Upon binding of uPAR to integrin, 
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conformational changes occur in α5β1 integrin, which subsequently forms an additional 
binding site for fibronectin and enhances cell binding to fibronectin [34]. Binding of 
fibronectin to α5β1 integrin induces focal adhesion kinase (FAK) phosphorylation and 
activates Ras-ERK signalling pathway, which is necessary for tumor growth in vivo (Fig3). 
 
 
 
Fig 3. Compilation of important interactions within the uPA systems leading to 
signalling events [35] 
 
 
Consistently, disruption of uPAR expression or FAK inhibition leads to tumor dormancy in 
human carcinoma cells [36, 37]. 
uPAR is able to transduces signals via interactions with the G protein-coupled receptors 
(GPCRs). For this interaction a motif between domain 1 and 2 has to be unmasked either by 
uPA binding to uPAR or by cleavage of domain 1 of uPAR, revealing a chemotactic epitope. 
Resulting cleaved peptide has chemoattractant activity, induces ERK1/2 phosphorylation and 
is considered as a ligand for GPCRs [38].  It has been shown that the family of formyl peptide 
receptor (FPR) is involved in transduction of chemotactic activity of uPA and subsequent 
cytoskeletal changes [9]. 
Interaction of uPAR with growth factor receptors is another possible mechanism for signal 
transduction. As a regulator of cell proliferation, uPAR overexpression constitutively 
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activates the EGFR pathway in many human cancer cell lines [3]. In these cell lines, uPAR 
overexpression activates EGFR in the absence of EGF. Co-immunoprecipitation experiments 
showed that EGFR directly interacts with α5β1 integrin and this interaction is enhanced by 
uPAR expression, leading to the activation of ERK signaling pathway and cell proliferation 
[39, 40]. 
 uPAR also associates with platelet-derived growth factor receptor beta (PDGFR-beta), which 
serves as a transmembrane adaptor for uPAR in vascular smooth muscle cells (VSMC) and 
mediates uPAR-directed signalling via the Jak/Stat pathway [41, 42]. It has been shown that 
the tyrosine phosphatase SHP-2 mediates these processes in uPA dependent manner that may 
contribute to the pathogenesis of the vascular remodeling [43]. 
uPAR signalling can occur through direct internalization. The lipoprotein receptor-related 
protein (LRP-1) binds uPAR–uPA–PAI-1 complexes and mediates endocytosis of multiple 
ligands, transports the uPAR and other membrane proteins into the endosomes and binds 
intracellular adaptor proteins involve in cell signalling [44].  
uPAR internalization also occurs via LRP-independent mechanism leading to subsequent 
nuclear translocation of uPAR. In this mechanism uPAR can directly affect transcriptional 
regulation of specific genes [45, 46].  
 
1.1.5. Role of uPAR in vasculature and vascular diseases 
Blood vessel growth and formation occur in different ways including vasculogenesis and 
angiogenesis [47]. Many studies have demonstrated the role of uPAR in these processes under 
pathological and physiological conditions [21, 48]. Angiogenesis involves a series of tightly 
regulated cellular processes initiated primarily by the VEGF [49, 50]. Inhibition of uPAR 
functional activity affects VEGF-mediated signaling and functional responses leading to 
significant decrease in the invasive potential of endothelial cells during angiogenesis [51, 52]. 
The uPA/uPAR system has been implicated in a broad spectrum of pathophysiological 
processes involved in occlusive and age-related cardiovascular diseases such as 
atherosclerosis, restenosis and aneurysm [53, 54]. It has been shown that both uPA and uPAR  
are upregulated in atherosclerotic lesions and involved in neointima formation and early 
lesion development [55-58].   
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uPA, uPAR and PAI-1 are essential for the regulation of migration and proliferation of 
leukocytes/macrophages, vascular endothelial- and smooth muscle cells [59-61]. This 
property of uPAR enables its active participation in wound healing and vascular remodeling. 
Moreover, uPAR regulates remodeling-related inflammatory responses serving as a modulator 
of immunocompetent receptors and of lymphocyte recruitment to the site of injury [62-66]. 
uPAR targeting in human blood vessels in organ cultures and in murine models for neointima 
formation in vivo, leads to strong inhibition of vascular remodeling [67, 68]. 
1.2. DNA damage response 
The DNA damage response (DDR) is a powerful intracellular network that has the potential to 
repair DNA damage and resolution of DNA replication problems. It is a key factor in the 
maintenance of genome stability comprised of sensor proteins that recognize damaged DNA; 
transducer proteins that relay and amplify the damage signal; and effector proteins that control 
cell cycle progression, DNA repair, apoptosis and senescence [69, 70]. The activation of 
signaling pathways depends on the type and extent of DNA damage and also the cell type. 
To maintain genomic stability, all types of DNA structural alterations including nicks, gaps, 
double-strand breaks (DSBs) and the alterations that block DNA replication must be detected. 
Different independent molecular complexes are known to be involved in sensing different 
types of DNA damage. Of the most importance are the phosphoinositide-3-kinase-related 
protein kinase (PIKK) family members ataxia-telangiectasia mutated (ATM), ataxia 
telangiectasia and Rad3 related protein (ATR) and DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs). While ATR activation is associated with single-stranded DNA and 
stalled DNA replication forks, ATM and DNA-PKcs respond mainly to DSBs. Many mediator 
complex such as Mre11-Rad50-Nbs1 (MRN), histone acetyltransferase Tip60, Topoisomerase 
IIβ-binding protein (TopBP1) and the protein phosphatase PP5 have been implicated in ATM, 
ATR activation and recruitment [71-73]. In mammals, ATR activation in response to DSBs 
appears to require ATM [74]. 
Mediators are proteins that act directly downstream of the ATM and ATR kinases. They play 
role in recruiting additional substrates and serve as a scaffold upon which to assemble 
complexes. During last few years many mediators such as mediator of DNA-damage 
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checkpoint 1 (Mdc1), p53 binding-protein 1(53BP1), MRN complex, Claspin, BRCT-repeat 
inhibitor of hTERT expression (Brit1) and microcephalin (Mcph1) has been discovered.                                                           
The histone H2A family (H2Ax) is one of the key mediators, which becomes phosphorylated 
by ATM, ATR and DNA-PKcs at the site of DNA damage [75]. This phosphorylation then 
directly recruits Mdc1 followed by subsequent recruitment of many additional factors such as 
53BP1, Checkpoint kinase 2 (Chk2) and p53 to the sites of damage leading to the generation 
of DNA damage foci. DDR foci are intracellular structures where DDR signalling originates. 
Elucidation of mechanisms of their formation and function is crucial to understand how DDR 
activities are exerted. Factors that lie upstream in the DDR signalling cascade and function 
close to the DNA damage site are constituents of DDR foci. 53BP1, a mediator with roles in 
recombination, Chk2 and p53 activation, is recruited to foci in an H2AX- and Mdc1-
dependent manner. 
DDR leads to induction of different pathways that are mostly regulated by protein kinases and 
their phosphorylation substrates. Over the past decade, single protein analysis of ATM and 
ATR substrate revealed many proteins that are phosphorylated in response to DNA damage 
agents that have known roles in DNA replication as well as DNA repair process such as 
nucleotide metabolism, transcription coupled repair, global excision repair, crosslink repair, 
mismatch repair and homologous recombination (HR) [76, 77]. These connections show the 
critical role that DDR pathways play in controlling DNA repair and genomic stability beyond 
their roles in controlling the cell cycle (Fig 5). 
Eukaryotes use many different mechanisms to repair chromosomal double-strand breaks 
(DSBs). In mammalian cells there are two major pathways for DNA-damage repair, namely 
nonhomologous end joining (NHEJ) and homologous recombination (HR). HR is an accurate 
form of repair, which requires an undamaged sister chromatid to act as a DNA template and 
functions only after DNA replication [78]. In contrast, NHEJ is active throughout the cell 
cycle entails straight forward ligation of DNA ends [79]. In addition to HR and NHEJ, there 
are increasing evidences for the existence of alternative end-joining pathways that directly 
ligate DNA ends in the absence of NHEJ [80-82]. 
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Studies revealed that genomes are not uniformly reparable and that some genomic loci, such 
as telomeric tracts, resist DNA-damage repair despite a global cellular competence for DNA 
repair [83, 84]. The irreparability of telomere may be the direct and unavoidable consequence 
of their functions in preventing chromosomal end-to-end fusions. The mechanisms seem to be 
evolutionarily conserved in yeast, rodents and primates [85].  
 
 
 
Figure 4. DNA damage response. The presence of a lesion in the DNA is recognized by 
various sensor proteins. Figure adapted and modified from Jackson, S. P.2009  [86]. 
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1.2.1. Telomere and DNA damage response 
Telomeres are specialized nucleo-protein structures form the end part of linear eukaryotic 
chromosomes [87]. Using cytogenetic approaches, it was shown that natural chromosome 
termini possess special properties that protected it from chromosomal abnormalities and DNA-
damage responses during telomere replication, recombination and erosion [88, 89]. Telomere 
structures consist of tandem repeat DNA sequences and associated proteins. Mammalian 
telomeric DNA is composed of G-rich tandem repeats of the (TTAGGG)n sequence (The G-
strand overhang), which in humans extends 10-15 kilo bases (Kb) whereas in inbred mouse 
strains it is approximately 40– 60 Kb [89].  
Cytologically, telomeres in a variety of plants and animals are heterochromatic, implying a 
high degree of DNA folding [90]. The bulk of telomeric DNA is double stranded, but the 
extreme terminus of telomeric DNA consists of a 3’ overhang of approximately 200 bases. The 
G-strand overhang is the substrate, to which telomeric repeats are added by telomerase [89]. 
1.2.2. Telomere binding proteins and their function 
The telomeric DNA is associated with a telomere specific protein complex, called shelterin, 
that functions to protect chromosome ends from all aspects of the DNA damage responds 
[89]. The components of shelterin were gradually identified over the past 10 years (Fig. 4). 
Telomeric-repeat binding factor1 (TRF1) was the first mammalian telomeric protein, isolated 
based on its in vitro specificity for double-stranded TTAGGG repeats typical of vertebrate 
telomeres [91]. TRF2 was identified, as a TRF1 paralog also possessing DNA-binding activity 
[92, 93]. Rap1 is an essential constitutive binding partner of TRF2 and depends on TRF2 for 
its telomeric localization and stability [94, 95]. TRF1-interacting nuclear factor (TIN2), TEL 
patch of telomere protein 1 (TPP1) and Protection of Telomeres 1 (POT1) are the other 
components of shelterin that bind to telomeric DNA, involve in telomere function [96-98].  
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Figure 5. Telomere structure. Telomeres are composed of TTAGGG repetitive sequences  
that terminate in a 3′ single-stranded (ss) overhang. Telomeric DNA is complexed by the six- 
shelterin protein, composed TRF1, TRF2, RAP1, TIN2, TPP1 and POT1. The ss overhang 
can invade the double-stranded region of the telomere to form a protective telomere loop with 
a ss displacement (D) loop at the invasion site [99]. 
 
 
 
TRF2 contains a TRFH domain, which directly binds the telomeric double-stranded DNA 
[93], In addition to telomeric DNA, TRF2 associates with various proteins involved in 
telosome assembly, telomere-length regulation, DNA replication, repair, end joining, 
recombination and cell-cycle control [89, 100]. Recent studies have further shown that TRF2 
serve as molecular platforms for the recruitment and assembly of the telomere interactome 
[88, 101]. Homozygous inactivation of either gene resulted in early embryonic lethality in 
mice [102]. In cultured cells, impairment of TRF2 function (dominant negative expression of 
TRF2∆B∆M) led to DNA-damage responses [103, 104]. Studies supported by in vitro assays 
showed that binding of TRF2 to telomeres is reduced by oxidative DNA damage [105]. 
However, the mechanisms of TRF2-mediated interaction and regulation remain mainly 
unknown.  
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1.2.3. The DNA damage hypothesis of telomere dysfunction 
In most organisms, telomeres that comprise stretches of short-tandem-DNA repeats are 
normally generated by the ribonucleoprotein complex telomerase. Excepting specialized cells 
such as stem cells, human cells generally do not express sufficient telomerase to counteract 
telomere shortening caused by the inability of the DNA replication machinery to fully 
replicate chromosomal ends. Thus, human telomeres generally shorten with each cell division 
[106].  
Telomere shortening leads to dysfunctional telomeres and uncapping of chromosomal ends that 
triggers responses similar to DNA damage signaling involves telomeric foci of phosphorylated 
histone H2AX and their co-localization with DNA repair and DNA damage checkpoint factors 
such 53BP1, Mdc1 and Nbs1 and activation of Chk1, Chk2, Mdc1 which are all down stream 
targets of ATM and p53. The DNA damage signal finally leads to growth arrest senescence or 
apoptosis [107].  
It is notable that telomeres are distinct from the rest of the genome in their DNA repair 
capacity and have been shown to inhibit non-homologous end joining (NHEJ) as a mechanism 
to prevent end-to-end chromosome fusions [108]. NHEJ is a major pathway for the repair of 
DSBs, can be inhibited in vitro by shelterin components, such as TRF2 [109]. For these 
reasons, it is speculated that telomeric repeats might be the preferential locations for DSBs, 
following exposure to DNA-damaging agents. The inability to repair DSBs by NHEJ at 
telomeric regions could be a major contributor to a persistent DDR involves in telomere 
dysfunction [85]. 
1.2.4. Senescence as a DNA damage response  
Cellular senescence has been defined as a state of permanent replicative arrest. The concept 
was first described by Hayflick and Moorhead in the early 1960s [110] and was latter 
attributed to the telomere shortening after several cell replication and lack of telomerase 
activity [111]. 
Beside induction of cellular senescence by critical telomere shortening, several other factors 
including DNA damaging agents and stimulation of several mitogenic pathways can also 
induce senescence irrespective of telomere length [112, 113]. The ATM checkpoint kinase, a 
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sensor of DSBs, and the p53 tumor suppressor protein, a substrate of ATM, are central to 
induction of senescence. Short telomeres and the agents that induce premature senescence all 
activate the DNA damage pathways; propose a unifying paradigm in which cellular 
senescence establishment is the result of irreparable telomeric DNA damage generation. 
However, still the detailed mechanisms of DNA damage induced senescence are not clear.   
Cellular senescence accompanied by set of characteristic morphological and physiological 
features that distinguish senescent cells not only from proliferating cells, but also from 
arrested quiescent or terminally differentiated cells [114]. Such senescence-associated features 
typically include irreversible proliferation arrest, enlarged cellular morphology, the activity of 
the senescence-associated β-galactosidase (SAβG) [115], nuclear hetero-chromatinization 
[116] and increased numbers of nuclear PML bodies [117], as well as many transcriptional 
and secretary changes such as up regulation of uPA, PAI-1, p21 cip1, p19 ARF p53, p16 [118, 
119]. Importantly, not all the features of cellular senescence are expressed in senescent cell 
and that none of the listed features are specific or unique to identify senescence cell. 
 1.2.5. Cellular senescence implication in vasculature  
Evidence supporting the hypothesis that age-associated changes in cardiovascular structure 
and function are risks for cardiovascular disease. 
Senescence in the vasculature was first identified by Fenton et al. in an experimental model of 
neointimal formation, in which balloon endothelial denudation was used as a stimulus to 
promote vascular cell replication [120]. In this model, SA-β-gal positive cells were found in 
both the neointima and the media of the injured vessel in endothelial and vascular smooth 
muscle cells [120]. Vascular senescence seems to be an in vivo phenomenon associated with 
atherosclerosis. Endothelial and vascular smooth muscle cells in atherosclerotic plaques show 
morphological characteristics of senescence [121, 122]. Indeed, growing evidence points to 
human atherosclerosis being characterized by enhanced DNA damage and DDR signaling, 
leading to senescence of vascular smooth muscle cells and death of other cells to yield 
atherosclerotic lesions [123]. 
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1.3. Ubiquitin-proteasome system (UPS) 
The ubiquitin-proteasome system (UPS) mediates the degradation of most cellular proteins, 
including short-lived proteins that control cell cycle, transcription, DNA repair, apoptosis and 
other cellular processes. The system comprises of two main steps: ubiquitination and 
proteasome-mediated degradation. During ubiquitination, ubiquitin molecules are attached to 
a substrate protein by a series of ATP dependent enzymatic reactions involving the ubiquitin-
activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3), and 
occasionally the ubiquitin chain-elongation factor (E4) [124].  
1.3.1. Ubiquitination mediating enzymes 
The ubiquitin activating enzyme E1 forms a thiol-ester bond between its active site cysteine 
and the carboxylterminal glycine of ubiquitin. Two E1 enzymes, which are able to activate 
ubiquitin have been identified in mammalian cells, namely, Ubiquitin-activating Enzyme 1-
like 2 (UBE1L2) and ubiquitin-like modifier-activating enzyme 6 (Uba6) [125, 126]. 
The activated ubiquitin on E1 is transferred to the active site cysteine of an E2 ubiquitin-
conjugating enzyme (UBC), by a trans-esterification reaction [124]. The human genome 
encodes over 40 UBCs, which contain a conserved 150-amino acid core domain that includes 
the cysteine which accepts an activated ubiquitin from E1 [127]. 
Ubiquitin ligases E3 family is involved in recognition of the substrates and transfer of 
ubiquitin from the E2 to the ε-amino group of a substrate lysine. Many E3s are discovered in 
eukaryotes and they are classified into four types: homologous to E6AP C-terminus (HECT) 
type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Seven in 
absentia homolog (SIAH) is a member of RING-finger Ubiquitin E3 enzymes involved in 
ubiquitination and proteasome-mediated degradation of specific proteins. The activity of this 
ubiquitin ligase has been implicated in the development of certain disease, the regulation of 
the cellular response to hypoxia and induction of apoptosis [128, 129]. Recent studies showed 
that E3 ubiquitin ligase SIAH1 is responsible for p53 mediated TRF2 ubiquitination and 
degradation related to telomere damage response and cell senescence [130]. 
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1.3.2. 26S proteasome structure 
The 26S proteasome is a 2.5 MDa protein complex consisting of two complexes: the catalytic 
20S core particle (CP) and the 19S regulatory particle (RP) [131]. The 20S CP is a barrel-
shaped structure of a stack of four seven subunit rings in a α7 b7 β7 α7 configuration. Both 
exterior rings contain one set of seven different α subunits; and both interior rings contain one 
set of seven different β subunits [132] . The proteolytic activity of the proteasome is found in 
the β-subunits [133]. The CP performs three types of catalytic activities: chymotrypsin-like, 
trypsin-like and caspase-like activities [133]. The 19S RP is a multi-subunit complex, which 
can be divided into two subcomplexes called the base and the lid (Fig. 1). The base consists of 
six ATPases (Rpt1-6) and three non-ATPase subunits (Rpn1, Rpn2 and Rpn13), whereas the 
lid includes at least nine non-ATPase subunits (Rpn3, Rpn5-9, Rpn11, Rpn12 and 
Rpn15/Sem1) [134]. The connection between the lid and the base is stabilized by the Rpn10 
subunit. Lack of structural data makes it difficult to fully understand how the RP subunits are 
arranged in the subcomplexes and how the RP stimulates the opening of the CP gate and 
facilitates substrate unfolding and translocation (Fig 6). 
1.3.3. Regulation of proteasomal activity 
Functional proteasomes require a highly regulated assembly of proteasomal subunits. Some 
associating proteins serve as the molecular scaffolds and chaperones that regulate the 
assembly of the 20S and 26S proteasomes [135]. Heat shock proteins and intermediate 
proteins have critical role in the maturation of the proteasome assembly complex [136]. 
Regulation of proteasomal activity also occurs at expression level through Rpn4 function. 
Studies showed that Rpn4 subunit of the 26S proteasome binds to the proteasome-associated 
control element (PACE) activating expression of α, β and 19S subunits [137]. Rpn4 itself is 
degraded within 2 min by the proteasomes and enables the subunit to dynamically stabilize 
proteasome levels within the cell [138]. 
Posttranslational modification of Rpn proteasomal subunits may affect phosphorylation of the 
ATPase subunits, Rpt6 in particular, by PKA and correlates with increased chymotryptic and 
tryptic activity. Alternatively, O-GlcNAcylation of Rpt2 serves as a master switch, shutting 
off proteolytic activity upstream of proteasome phosphorylation [139]. Binding of the 
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activator and inhibitor proteins to the either end of the 20S provides another way to control 
proteasomal activity [140]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.Schematic diagram of the 26S proteasome. The 26S proteasome consists of the 
20S core particle and the 19S regulatory particle [141] 
 
 
1.3.4. Regulatory role of Ubiquitin-proteasome system in DNA damage      
          response  
Protein ubiquitination apart from targeting proteins for degradation is emerging as an 
important regulatory element implicated in many cellular processes as diverse as gene 
transcription, DDR, receptor trafficking, endocytosis and cell cycle control.  
The regulatory role of UPS in DDR in both protein turnover and protein recruitment has been 
well defined. DDR utilizes multiple classes of ubiquitin-binding motifs to coordinate 
signaling and repair [142, 143]. Indeed, many of the DDR transducers such as breast cancer 
type/BRCA-associated ring domain (BRCA1/BARD), Fanconi anemia complementation 
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group L (FANCL), Rad 18, murine double minute (Mdm2) are enzymes that catalyze 
ubiquitination of proteins.  
Ubiquitin conjugation via alternative lysine residues mediates specific protein-protein 
interactions. Therefore proteins can be modified not only with ubiquitin polymers composed 
of single isopeptide linkages but also with heterogeneous ubiquitin chains highlighting the 
vast potential for multiple levels of regulation [101]. Still much more remains to be 
discovered about how ubiquitin modification in DDR controls protein function, activity and 
recruitment. 
The most common function of UPS is protein degradation through the proteasomal activity. 
Suppressor of an exocyst mutant (Sem1), deleted in split hand/split foot protein 1 (DSS1) and 
split hand-split foot malformation (SHFM1) protein are subunits of the 19S proteasome in 
both yeast and human cells that are recruited with the 19S and 20S proteasomes to DNA DSB 
in vivo and are required for efficient repair of DSB through HR and NHEJ mechanisms [144]. 
Human DSS1/SHFM1 physically binds to BRCA2/FANCD1 and is required for its stability 
and function [16, 145].  
It is shown that proteasome inhibitors inhibit both monoubiquitination and nuclear foci 
formation of DNA damage–signaling processes, such as foci formation of phosphorylated 
ATM, 53BP1, NBS1, BRCA1, and RAD51 [86].  
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Objectives of the thesis 
There are two general aims of this thesis; the first was to understand the role of uPAR in DNA 
damage induced senescence as an irreparable consequence of telomeric dysfunction and the 
second was to obtain better information on the involvement of uPAR in repair mechanism of 
DNA damage response.  
In the first part, the focus was on TRF2, the main component of telomere structure and its 
regulation during drug induced senescence. It was aimed to study uPAR possible role in TRF2 
regulation and to elucidate the underlying mechanism. This part of the thesis was motivated 
by previous evidence suggesting the implication of uPA/uPAR system in senescence process. 
In the second part, the focus was on involvement of uPAR in DNA repair mechanisms, based 
on its regulatory role in UPS. This part was motivated by the findings resulted from the first 
part of study on the role of uPAR in UPS and also by several clues from different studies 
reporting the involvement of uPA/uPAR in pathways triggered by DNA damage. 
The specific aims of these manuscripts are summarized concisely below: 
Manuscript 1 
1. Evaluate the effect of low doses of the anti-cancer drug Doxorubicin on VSMC 
2. Evaluate the effect of Doxorubicin on TRF2 during senescence response    
3. Elucidate the uPA/uPAR system requirement for senescence response 
4. Investigate the mechanism of uPAR mediated TRF2 proteasomal degradation  
5. Investigate the mechanism of uPAR mediated TRF2 ubiquitinaton   
Manuscript 2 
1. Evaluate the effect of uPAR depletion in DNA damage repair mechanisms and cell 
survival  
2. Evaluate the functional behavior of Rpn7 proteasomal compartment during DNA 
damage response and implication of uPAR 
3. Identify the regulatory factors involved in Rpn7 regulation during uPAR mediated 
DNA damage response  
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4. Evaluate the significance of SHP-2 in uPAR mediated DNA damage response  
  
Elucidation of regulatory factors and pathways involved in DNA damage response 
mechanisms may lead to novel therapeutic avenues for age related diseases and cancer. 
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3.1. Manuscript 1 
Urokinase receptor mediates Doxorubicin-induced vascular smooth muscle 
cell senescence via proteasomal degradation of TRF2 
 
Journal of vascular biology, 2013;50:109-123 
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 Urokinase Receptor Mediates Doxorubicin-Induced 
Vascular Smooth Muscle Cell Senescence
via Proteasomal Degradation of TRF2 
 Mahshid Hodjat    Hermann Haller    Inna Dumler    Yulia Kiyan 
 Nephrology Department, Hannover Medical School,  Hannover , Germany 
VSMC senescence. Our results demonstrate that uPAR con-
trols the ubiquitin-proteasome system in VSMC and regu-
lates doxorubicin-induced TRF2 ubiquitination and protea-
somal degradation via this mechanism. Therefore, VSMC
senescence induced by low doses of doxorubicin may con-
tribute to vascular damage upon doxorubicin treatment. 
uPAR-mediated TRF2 ubiquitination and proteasomal deg-
radation are further identified as a molecular mechanism un-
derlying this process.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Clinical use of doxorubicin, a powerful anti-cancer 
drug of the anthracycline family, is limited because of its 
acute and chronic cardiovascular side effects manifested 
by cardiomyopathy  [1, 2] . Molecular mechanisms under-
lying doxorubicin cardiotoxicity remain, despite inten-
sive studies, poorly understood. Correspondingly, clini-
cal approaches to prevent and minimize its toxic effects 
on the heart are still missing. A growing body of evidence 
indicates that cancer treatment with anthracyclines re-
sults, beyond cardiomyopathy and refractory congestive 
heart failure, in further forms of cardiovascular diseases 
 Key Words 
 Cell senescence   Doxorubicin   Telomeric repeat binding 
factor 2   Ubiquitin-proteasome system   Urokinase 
receptor 
 Abstract 
 The anthracycline doxorubicin is a widely used effective an-
ti-cancer drug. However, its application and dosage are se-
verely limited due to its cardiotoxicity. The exact mecha-
nisms of doxorubicin-induced cardiotoxic side effects re-
main poorly understood. Even less is known about the 
impact of doxorubicin treatment on vascular damage. We 
found that low doses of doxorubicin induced a senescent 
response in human primary vascular smooth muscle cells 
(VSMC). We observed that expression of urokinase receptor 
(uPAR) was upregulated in response to doxorubicin. Further-
more, the level of uPAR expression played a decisive role in 
developing doxorubicin-induced senescence. uPAR silenc-
ing in human VSMC by means of RNA interference as well as 
uPAR knockout in mouse VSMC resulted in abrogation of 
doxorubicin-induced cellular senescence. On the contrary, 
uPAR overexpression promoted VSMC senescence. We fur-
ther found that proteasomal degradation of telomeric re-
peat binding factor 2 (TRF2) mediates doxorubicin-induced 
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affecting the vascular wall  [3] . However, little is known 
about its vascular toxicity. A couple of reports document-
ed damage to the vascular endothelium in response to 
doxorubicin  [4] , which is most likely related to doxorubi-
cin-induced apoptosis of endothelial cells  [5, 6] . Even less 
is known about the effects of doxorubicin treatment on 
vascular smooth muscle cells (VSMC), though deregula-
tion of these cells is one of the key events contributing to 
negative vascular remodeling and dysfunction  [7] .
 It is believed that the cardiotoxic effects of doxorubicin 
are related to increased oxidative stress and reactive oxy-
gen species (ROS) generation  [1, 2] . Increasing evidence 
indicates, however, that the use of antioxidants failed to 
prevent anthracycline-induced cardiovascular side effects 
both in clinical trials and animal models, and thus fur-
ther, still unknown essential mechanisms may be involved 
 [2] . Moreover, these mechanisms seem to be different de-
pending on the doxorubicin dose. Though treatment with 
both low and high doses of doxorubicin culminates in car-
diovascular disorders, their cellular effects are not the 
same  [8] . A number of recent studies report that doxoru-
bicin can activate the ubiquitin-proteasome system (UPS) 
and mediate by this way degradation of transcription fac-
tors and other key proteins possibly underlying doxorubi-
cin cardiotoxicity  [9] . We have recently demonstrated that 
the multifunctional urokinase (uPA)/urokinase receptor 
(uPAR) system, which is an important regulator of VSMC 
in health and disease  [10] , mediates the specific ubiqui-
tination and proteasomal degradation of proteins deter-
mining VSMC functional behavior. We further found 
that uPAR deficiency resulted in decreased proteasomal 
activity in blood vessels of uPAR–/– mice  [11] .
 In this study, we examined the effects of low doses of 
doxorubicin on cellular and functional properties of hu-
man VSMC. We investigated the contribution of UPS to 
these effects. We hypothesized that uPAR may orchestrate 
the outcome of doxorubicin-induced VSMC responses by 
regulating UPS. We demonstrate that doxorubicin induc-
es VSMC senescence that may contribute to vascular 
damage. We further show that uPAR controls this process 
via the regulation of telomeric repeat binding factor 2 
(TRF2) ubiquitination and proteasomal degradation.
 Methods 
 Cell Culture and Doxorubicin Treatment 
 Human primary umbilical artery VSMC were isolated from 
the umbilical artery using an explant technique in VascuLife SMC 
culture medium (CellSystems  ; Biotechnologie Vertrieb GmbH, 
St. Katharinen, Germany). The procedure conforms to the Decla-
ration of Helsinki and was approved by the local ethics commit-
tee. First-passage fibroblasts were removed from the culture by 
cell separation using monoclonal anti-fibroblast antibodies (anti-
CD90; Dianova GmbH, Hamburg, Germany) and magnetic Dy-
nabeads  goat anti-mouse IgG (Invitrogen, Carlsbad, Calif., 
USA). VSMC were used between passages 2 and 4. Aortic VSMC 
were isolated from male uPAR–/– mice and uPAR+/+ (wild-type, 
WT) mice as controls (all on C57/BL6 background, age 10–12 
weeks). All animal experiments were carried out according to the 
European Commission guidelines and were approved by the Eth-
ics Committee of the Hannover Medical School. Animals were 
euthanized by intravenous injection of 200   l of 2% Avertin solu-
tion. The aortas were dissected, cut into pieces that were 1–2 mm 
on a side and subjected to enzymatic digestion as described  [12] . 
VSMC were cultivated in DMEM (Dulbecco’s modified Eagle’s 
medium) supplemented with 10% (v/v) fetal bovine serum. For 
induction of senescence, VSMC and umbilical artery SMC 
(UASMC) were exposed to doxorubicin (Sigma) treatment at dos-
es of 0.25, 0.5 and 1   M doxorubicin for 3 h in medium containing 
no serum. Cells were then washed 3 times with PBS and incubat-
ed in growth medium.
 BAY 11-7085, a nuclear factor (NF)   B inhibitor, was pur-
chased from Enzo Life Sciences (Lausen, Switzerland). VSMC 
were pretreated with 10   M BAY 11-7085 prior to doxorubicin 
treatment. After cell washing and medium exchange, BAY was 
added to the growth medium. The proteasome inhibitor MG132 
was purchased from Calbiochem (Merck KGaA, Darmstadt, Ger-
many). Cells were pretreated with 10   M MG132 prior to doxoru-
bicin treatment. After cell washing and medium exchange, 
MG132 was added to the growth medium.
 Senescence-Associated   -Galactosidase Activity 
 Senescence-associated   -galactosidase (SA-Gal) staining was 
performed 3 days after doxorubicin treatment according to the 
methods described previously  [13] . Cells were counterstained 
with 0.1   g/ml DAPI solution for 5 min. The numbers of   -Gal-
positive cells were scored under bright field per total cell number 
in the same field using a Leica DM LB fluorescence microscope 
(Leica Microsystems). Each experiment was carried out in tripli-
cate and at least 500 cells were scored in total in 5 different ran-
dom fields. 
 Alternatively, fluorogenic substrate (C12FDG; Molecular 
Probes, Invitrogen) was used for measuring   -Gal activity using 
flow cytometry as described  [14] . FACS analysis was performed 
on FACSCalibur (BD Biosciences). Summit software (Dako) was 
used for analyzing the study data.
 Apoptosis 
 Cell apoptosis characterized by accumulation of phosphati-
dylserine on the extracellular surface of the membrane was stud-
ied using the annexin V apoptosis detection kit (Santa Cruz Bio-
technology, Santa Cruz, Calif., USA). Cells were stained accord-
ing to the manufacturer’s instructions and subsequently analyzed 
by flow cytometry (FACSCalibur). 
 Cell Proliferation 
 Cell proliferation was quantified based on the measurement of 
BrdU (5-bromo-2-deoxyuridine) incorporation during DNA syn-
thesis using a colorimetric cell proliferation ELISA kit (Roche Ap-
plied Bioscience).
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 Plasmid Construction and Nucleofection 
 Small interfering RNA (siRNA) for downregulation of uPAR, 
TRF2 and Siah1, and control silencing RNA was obtained from 
Santa Cruz Biotechnology and transfected with human UASMC 
using Amaxa Nucleofector TM (Lonza). A basic primary smooth 
muscle cell nucleofector kit (Lonza) was used according to the 
manufacturer’s instructions. 
 For green fluorescent protein (GFP)-uPAR overexpression, the 
lentivirus pDEST-lenti transfer vector was generated by blunt li-
gation gateway cassette rfa-verB (Invitrogen) at  Pme I and  Sma I 
sites of the pLV-tRKRAB-Red vector (Tronolab). Entry clones for 
the transfer of GFP-uPAR were produced by cloning the PCR 
products in the pENTR/D TOPO plasmid (Invitrogen). The GFP-
uPAR vector (kindly provided by N. Sidenius) served as template 
for PCR  [15] . For GFP-uPAR overexpression, pEXPR clones were 
generated by site-specific recombination between pDEST-lenti 
and pENTR/D TOPO-M-CSFR by Gateway LR Clonase enzyme 
mix (Invitrogen). (GFP-uPAR sense primer: 5  -tcagatctcgagctgcc-
ctc and GFP-uPAR anti-sense primer: 5  -aggtccagaggagagtgcct.) 
For experiments with GFP-uPAR constructs, pCMV-dR8.74, 
pMD.2G (Tronolab) and pEXPR plasmids were co-transfected 
(using a 3: 2:1 ratio of pEXPR:pCMV-dR8.74:pMD2G) into 293T 
cells by PerFectin transfection reagent (Genlantis, San Diego, 
 Calif., USA), as recommended by the manufacturer. Forty-eight 
hours after transfection, the viral particles containing cell super-
natants were harvested, filtered, concentrated and stored at –70  °  C 
for future use. TRF2-IRESS-enhanced GFP plasmid was a gift 
from Dr. de Lange  [16] (Addgene plasmid No. 19798).
 Immunostaining 
 Cells grown on coverslips were fixed with 2% formaldehyde, 
permeabilized in 0.1% Triton X-100 for 3 min and blocked with 
3% (w/v) BSA/PBS at 4  °  C overnight. After 24 h, cells were labeled 
with monoclonal mouse anti-TRF2 (Imgenex) and subsequently 
with corresponding Alexa Fluor  488- or Alexa Fluor 594-conju-
gated secondary antibody (Invitrogen) for 1 h at room tempera-
ture. DRAQ5 (BioStatus) was applied as nuclear stain. Cells were 
then mounted with mounting medium (Aqua-Poly-Mount; Poly-
sciences) and analyzed on a Leica TCS-SP2 AOBS confocal micro-
scope. For immunostaining of mouse aortic VSMC, cells were in-
cubated with 5% mouse serum in PBS followed by 1 h incubation 
with 5% normal goat serum. 
 Preparation of Cell Lysates, Immunoprecipitation and 
Western Blotting  
 Cultured cells were lysed in RIPA buffer containing 1 m M 
PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 m M Na 3 VO 4 and 
1 m M NaF and incubated for 10 min at 4  °  C. The lysates were cen-
trifuged at 10,000 rpm for 10 min. TRF2 was immunoprecipitated 
from 600   g of total cell lysate with 4   g of specific polyclonal 
antibodies against TRF2 (Santa Cruz). After 3 h, immunocom-
plexes were precipitated with A/G PLUS-agarose beads. Precipi-
tates were washed 3 times in PBS containing protease inhibitors 
and subjected to SDS electrophoresis. The membranes were de-
veloped with antibodies against p53, p21, p16 (Santa Cruz), uPAR 
(R&D Systems). Antibody against ubiquitin for detecting ubiqui-
tination of immunoprecipitated TRF2 was purchased from Santa 
Cruz.
 Quantitative Real-Time Polymerase Chain Reaction Analysis 
 Total RNA was isolated from UASMC using the QiaSpin mini-
prep kit (Qiagen) according to the manufacturer’s protocol. Taq-
Man analysis was performed on a LightCycler  480 real-time 
PCR system using LightCycler 480 RNA Master Hydrolysis 
probes (Roche Applied Sciences). The following primers were 
used: uPAR (human); sense 5  -ACCACCAAATGCAACGAGG-
3  ; antisense 5  -GTAACACTGGCGGCCATTCT-3  ; probe 6-FAM-
CAATCCTGGAGCTTGAAAATCTGCCG-TAMRA, GAPDH 
(human); sense 5  -GAAGGTGAAGGTCGGAGTC-3  ; antisense 
5  -GAAGATGGTGATGGGATTC-3  ; 6-FAM-CAAGCTTCCC-
GTTCTCAGCC-TAMRA probe; TRF2 (human); sense 5  -GGA-
GGAGGCGGGAGTAGC-3  ; antisense 5  -ACTTGAGCACCCA-
GCGATTG-3  ; probe 6-FAM-TGCCTCTTCCAGCCGTGCCT-
CC-TAMRA.
 Proteasomal Activity Assay 
 Total proteasomal activity in cell lysates was measured using 
the 20S proteasomal assay kit (Cayman Chemical Company, Ann 
Arbor, Mich., USA) as described by the manufacturer. In brief, 
UASMC were grown in a 96-well plate and treated with different 
concentrations of doxorubicin according to the stated protocol. 
The plate was then centrifuged at 500  g for 5 min and the cells 
were washed with 20S proteasome assay buffer. Lysis buffer was 
added to each well, and the plate was shaken for 30 min at room 
temperature. The plate was then centrifuged at 1,000  g for 10 min, 
and supernatant from each well was transferred to the corre-
sponding wells in a black 96-well plate. Thereafter, 10   l of assay 
buffer and 10   l of the substrate (SUC-LLVY-AMC) were added. 
After 1 h of incubation at 37  °  C, the plate was read using a Magel-
lan GENIOUS (Tecan, Männedorf, Switzerland) at 360 (excita-
tion) and 480 nm (emission). The enzymatic activity was normal-
ized to the protein concentration. The results are reported as 
means  8 SD.
 ROS Detection 
 ROS were detected fluorescently using 5 (and 6)-carboxy-2  ,7  -
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA; Invi-
trogen). VSMC were loaded with 5   M of the dye for 30 min at 
37  °  C, then washed 3 times with cell culture medium and treated 
with different concentrations of doxorubicin for 3 h. Fluorescence 
was measured after 3, 6 and 24 h.
 Chromatin Immunoprecipitation and Telomere Detection 
 Telomeric association of TRF2 was assessed using chromatin 
immunoprecipitation (ChIP) followed by DNA isolation, dot blot, 
hybridization and chemiluminescence detection of telomeric 
DNA. ChIP was performed according to a previously described 
protocol  [17] . Briefly, cells were fixed with 1% formaldehyde for 
10 min at 18  °  C. Paraformaldehyde was quenched by glycine (125 
m M ). Cells were washed and scraped in RIPA buffer. DNA was 
sheared by sonication. Lysates were incubated overnight with an-
ti-TRF2 antibody and salmon sperm DNA-saturated protein 
A/G-agarose to immunoprecipitate TRF2. DNA was purified us-
ing Chelex-100 resin. Input DNA samples were purified along 
with the immunoprecipitates. Isolated DNA samples were trans-
ferred to the HyBond N+ membrane (Amersham) under vacuum. 
Hybridization and detection of telomeric DNA was performed 
using the Telo TAGGG telomere length assay kit (Roche Applied 
Biosciences) according to the manufacturer’s protocol. 
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 Statistical Analysis 
 All experiments were performed at least three times. ‘n’ repre-
sents the number of independent experiments. For Western blot-
ting, one representative blot out of at least three is shown. Statisti-
cal significance (p  ! 0.05) was analyzed using Student’s t test. 
Values of p  ! 0.05 were regarded as statistically significant.
 Results 
 Doxorubicin Induces VSMC Senescence 
 High doses of doxorubicin lead to apoptotic cell death, 
as shown for cardiomyocytes and endothelial cells  [5, 18, 
19] . When exposed to low doxorubicin doses, cardiomy-
ocytes revealed a senescence-like phenotype  [20] . Since 
nothing is known about the effects of doxorubicin treat-
ment on VSMC function, we first examined dose-depen-
dent cell responses. We observed that low doxorubicin 
concentrations induced cellular senescence in VSMC. 
Thus, VSMC expressed -Gal activity that serves as a 
marker for senescence, as determined by microscopy 
( fig.  1 a) and flow cytometry ( fig.  1 b). Doxorubicin in-
duced -Gal activation in a dose-dependent manner at a 
concentration range of 0.25–1   M ( fig. 1 c). Induction of 
the senescent phenotype is generally characterized by 
impaired proliferative responses. In agreement with 
these observations, VSMC proliferation was inhibited in 
response to senescence-inducing doxorubicin concen-
trations ( fig. 1 d). Similar to cellular responses of other 
cell types, high doses of doxorubicin resulted in VSMC 
apoptosis ( fig. 1 e). Senescence-associated proteins such 
as p53 and p21 were dose-dependently upregulated in 
VSMC following doxorubicin treatment, whereas ex-
pression of p16 did not differ after doxorubicin treatment 
( fig. 1 f).
 uPAR Mediates Doxorubicin-Induced Senescence in 
VSMC 
 uPAR is an important regulator of functional respons-
es of VSMC, such as proliferation, migration and differ-
entiation  [21–23] . However, whether or not uPAR is in-
volved in the propagation of the senescence signal in 
these cells is not known. uPAR expression in VSMC was 
upregulated in response to doxorubicin in a dose-depen-
dent manner. This increase in uPAR expression was not-
ed at both protein and mRNA levels, as reflected by West-
ern blotting and TaqMan analysis ( fig. 2 a, b). On the con-
trary, uPA expression was downregulated by doxorubicin 
treatment ( fig. 2 c). Further experimental settings, name-
ly confocal microscopy, confirmed uPAR upregulation in 
VSMC following low-dose doxorubicin ( fig. 2 d). Expres-
sion of uPAR is regulated by several signaling pathways 
and transcription factors. NF  B is an important regula-
tor of uPAR expression  [24] . Since doxorubicin treatment 
often leads to NF  B activation, we next tested whether 
uPAR expression is upregulated by doxorubicin via the 
NF  B pathway. As shown in  figure 2 e, VSMC treatment 
with an NF  B inhibitor abrogated doxorubicin-induced 
upregulation of uPAR expression.
 To elucidate whether the observed upregulation of 
uPAR may be involved in the molecular machinery un-
derlying doxorubicin-induced VSMC senescence, uPAR 
downregulation was performed by means of interfering 
RNA combined with cell nucleofection. This approach 
provides uPAR silencing with a high efficiency rate 
( fig.  3 a). VSMC nucleofected with control siRNA re-
sponded to doxorubicin with a senescent phenotype, 
which was strongly abrogated in uPARsi cells ( fig. 3 b). A 
similar effect was observed in mouse VSMC. Thus, WT 
VSMC responded to doxorubicin treatment with much 
higher senescence than VSMC from uPAR–/– mice 
( fig. 3 c). By contrast, uPAR overexpression by VSMC len-
tiviral infection ( fig. 3 d) resulted in increased cellular se-
nescence ( fig. 3 e). These data suggest that uPAR is rather 
an active regulator of the senescence process in VSMC 
than just a marker of the senescent cell phenotype.
 Doxorubicin Induces uPAR-Mediated Proteasomal 
Activity and Ubiquitination of TRF2 in VSMC 
 Next, we addressed molecular mechanisms underly-
ing uPAR-mediated senescence in VSMC in response to 
low-dose doxorubicin. Our data showed that doxorubi-
cin at concentrations of up to 5   M did not induce any 
significant oxidative stress in human VSMC (data not 
shown). Only cell treatment with 10   M doxorubicin re-
sulted in increased ROS production (1.21  8 0.20 times 
in SiCo VSMC and 1.4  8 0.31 times in uPARsi VSMC). 
There was no statistically significant difference in 10-  M 
doxorubicin-induced ROS production by SiCo and 
uPARsi VSMC. Therefore, uPAR-mediated VSMC se-
nescence induced by doxorubicin doses  ! 1   M is medi-
ated by other mechanisms than oxidative stress induc-
tion.
 We then provided prove for the hypothesis that these 
mechanisms may be related to uPAR interfering with 
doxorubicin-directed effects on UPS. In agreement with 
observations done on other cell types, doxorubicin treat-
ment induced an increase in proteasomal activity in 
VSMC. However, in uPARsi cells, this doxorubicin-in-
duced effect was abrogated ( fig. 4 a). Similarly, uPAR–/– 
mouse VSMC failed to upregulate proteasomal activity
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in response to doxorubicin treatment ( fig. 4 b). These data 
suggest a regulatory role for uPAR in UPS control in 
VSMC in response to doxorubicin.
 Recent reports suggest that telomere dysfunction has 
an impact on apoptotic cell death and senescence  [25] . In 
particular, telomere binding factors (TRF1 and TRF2) at-
tract more and more attention as key regulators of the 
senescence program in cancer and aging  [26] . Therefore, 
we aimed to determine whether TRF2 might serve as a 
substrate for uPAR-related ubiquitination and protea-
somal degradation and thus may trigger doxorubicin-in-
duced, uPAR-controlled senescence in VSMC. To get an 
idea about the functional relevance of TRF2 for doxoru-
bicin-induced VSMC senescence, TRF2 downregulation 
by means of siRNA was performed ( fig. 4 c). TRF2 was 
downregulated either alone or concomitant with uPARsi. 
Decreased protein expression was ascertained 24 h after 
cell nucleofection. At that time point, cells were treated 
with doxorubicin to induce senescence. Doxorubicin-in-
duced senescence was significantly increased in TRF2si 
cells, providing evidence for TRF2 involvement in this 
process ( fig.  4 d). Further downregulation of uPAR in 
TRF2si cells failed to rescue cells from doxorubicin-in-
duced senescence ( fig. 4 c, d). To confirm the specificity 
of the TRF2 downregulating effect on doxorubicin-in-
duced senescence, we have performed a rescue experi-
ment by expressing TRF2 from the TRF2-IRESS-
enhanced GFP plasmid  [16] in cells nucleofected with 
TRF2si RNA. Control cells were co-nucleofected with 
empty vector. As shown in  figure 4 e, replenishing TRF2 
abrogates doxorubicin-induced senescence. Together, 
these observations confirm that TRF2 is causative for 
doxorubicin-induced senescence and that uPAR and 
TRF2 are parts of the same senescence pathway in VSMC.
 uPAR Controls Nuclear Accumulation and DNA 
Binding of TRF2 
 To provide further evidence for uPAR-directed regu-
lation of TRF2, we determined the TRF2 level in VSMC 
and found decreased TRF2 protein expression in re-
sponse to doxorubicin. This effect was, however, abol-
ished by uPAR downregulation in uPARsi cells ( fig. 5 a). 
Consistent with these observations, immunocytochemi-
cal studies documented a decreased amount of TRF2 in 
cell nuclei in doxorubicin-treated cells. Similar to the 
Western blotting data, this effect was prevented by uPAR 
silencing ( fig. 5 b). To further substantiate these findings, 
we performed additional experiments using uPAR–/– 
mouse VSMC. The decrease in TRF2 protein and in its 
nuclear accumulation in response to doxorubicin was 
abolished in uPAR–/– cells ( fig. 5 c, d) consistent with the 
observations done on human VSMC with downregulated 
uPAR.
 Decreased TRF2 protein expression might be achieved 
either by inhibition of its expression or proteasomal deg-
radation of TRF2. We performed TaqMan analysis to de-
termine TRF2 mRNA expression in doxorubicin-treated 
cells. As shown in  figure 5 e, the TRF2 mRNA level did 
not change, suggesting involvement of proteasomal deg-
radation. Indeed, inhibition of proteasome with MG132 
abrogated doxorubicin-induced TRF2 degradation 
( fig. 5 f).
 We next analyzed if TRF2 is associated with the cor-
responding telomeric DNA in VSMC after doxorubicin 
treatment using ChIP. ChIP analysis revealed a dose-de-
pendent inhibition of the TRF2/DNA complex in re-
sponse to cell stimulation with doxorubicin. This effect 
was, however, completely abolished in cells with down-
regulated uPAR ( fig.  5 g). These data suggest that in 
uPARsi VSMC doxorubicin-induced degradation of 
TRF2 is impaired and TRF2 remains bound to telomeric 
DNA. It might explain the mechanism of uPAR interfer-
ence with the program of doxorubicin-induced VSMC se-
nescence.
 Protein ubiquitination is a general process preceding 
and controlling protein degradation by UPS  [27] . There-
fore, we analyzed TRF2 ubiquitination in VSMC in re-
sponse to doxorubicin and the effect of uPAR downregu-
lation on this process. Immunoprecipitation of TRF2 fol-
lowed by immunoblotting with anti-ubiquitin antibody 
was performed. Indeed, increased ubiquitination of TRF2 
was noted in doxorubicin-treated cells that was abolished 
in uPARsi VSMC ( fig. 6 a). Interestingly, the basal level of 
TRF2 ubiquitination was markedly increased in uPARsi 
VSMC. The membrane was then stripped and developed 
with anti-TRF2 antibodies to distinguish ubiquitinated 
TRF2 from other ubiquitinated proteins that can associ-
ate with TRF2 in immunoprecipitation. The data con-
firmed that ubiquitination of TRF2 itself is induced by 
doxorubicin in uPAR-dependent manner ( fig.  6 a, right 
panel). Similar results were obtained when WT and 
uPAR–/– mouse VSMC were used for the immunopre-
cipitation assay ( fig. 6 b). On the contrary, when uPAR ex-
pression was upregulated by means of VSMC lentiviral 
infection, TRF2 ubiquitination in untreated cells was de-
creased and doxorubicin-induced ubiquitination of TRF2 
was present ( fig. 6 c). Thus, downregulation of uPAR ex-
pression has dual effects on the level of TRF2 ubiquitina-
tion. On the one hand, it markedly induces basal TRF2 
ubiquitination. On the other hand, downregulation of 
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uPAR prevents doxorubicin-induced ubiquitination and 
degradation of TRF2. Increased basal TRF2 ubiquitina-
tion in the absence of doxorubicin treatment might result 
from impaired proteasomal degradation of proteins that 
we observed in uPAR knockout cells and changed activ-
ity of TRF2-ubiquitinating and -deubiquitinating en-
zymes.
 In a previous study, Siah1, a p53-inducible E3 ubiqui-
tin ligase, was implicated in TRF2-mediated senescence 
 [28] . Next, we tested if uPAR influences TRF2 ubiquitina-
tion via the p53-Siah1 pathway. First, Ser 15 phosphoryla-
tion of p53 in doxorubicin-treated VSMC was assessed. 
As illustrated in  figure 7 a, p53 phosphorylation is in-
creased after doxorubicin treatment. Again, in uPARsi 
VSMC, baseline p53 phosphorylation was higher than in 
control cells. Siah1 expression was also upregulated in 
uPARsi VSMC ( fig. 7 b). These data confirm other obser-
vations done in this study and might explain increased 
TRF2 ubiquitination in uPARsi VSMC. Further, we 
downregulated Siah1 expression alone and concomitant 
with uPAR ( fig. 7 c) and performed an immunoprecipita-
tion assay. As shown in  figure 7 d, in the absence of Siah1, 
the level of ubiquitinated TRF2 is decreased even in 
uPARsi VSMC. The doxorubicin-induced response is 
also abrogated. These data show that uPAR downregula-
tion influences ubiquitination of TRF2 via both Siah1-
mediated ubiquitination and downregulation of protea-
somal degradation. Whether TRF2 deubiquitination is 
also affected by uPAR remains to be elucidated.
 Discussion 
 TRF2 is a telomere-binding factor of the telomere-cap-
ping protein-complex shelterin and plays a critical role in 
cancer and aging. TRF2 maintains the structure of telo-
mere termini and is essential to prevent the activation of 
factors triggering a DNA-damaging response that may 
lead to the induction of apoptosis or cellular senescence 
 [26, 29] . Though decisive functions of TRF2 and its re-
lated proteins in controlling genetic stability are well rec-
ognized, nothing is known, despite intense research, 
about what factors provide TRF2 regulation in physiolog-
ical and pathophysiological conditions. It has been sug-
gested that elucidation of these factors may lead to novel 
therapeutic avenues for cancer and aging  [26] . Our study 
identifies uPAR as one of the factors regulating TRF2 in 
human VSMC in response to low doses of doxorubicin 
and suggests that uPAR may be a target to affect  cardio-
vascular side effects of doxorubicin treatment.
 uPAR is a multifunctional receptor that – in addition 
to plasminogen activation – initiates intracellular signal-
ing and regulates cell migration, invasion and prolifera-
tion  [30, 31] . Little is known, however, about the involve-
ment of uPAR in cellular senescence. Recent studies
report on uPAR-mediated mechanisms underlying
senescence-associated cellular events in a cancer cell line 
 [32] . Interestingly, in contrast to our results, in those cells, 
uPAR loss by means of siRNA resulted in increased cell 
senescence related to decreased activity in the FAK/PI3K/
Akt signaling pathway. Cell type specificity of uPAR-re-
lated cellular mechanisms is well known. Whether and 
how the uPA/uPAR system interferes with doxorubicin 
treatment in cancer cells remains to be determined. Soli-
tary studies report increased expression of uPA, but not 
uPAR, in human lung carcinoma cells in response to 
higher doxorubicin concentrations  [33, 34] . On the other 
hand, increased uPAR expression was also associated 
with a senescence-associated secretory phenotype in dif-
ferent cell lines  [35] . uPAR was upregulated in VSMC 
treated with low doxorubicin concentrations. We provide 
evidence that increased uPAR expression in cells under-
going senescence was not a coincidence but rather a re-
quirement for the senescence program propagation in re-
sponse to doxorubicin. Thus, VSMC senescence was ab-
rogated in uPARsi cells and cells from uPAR–/– mice, 
whereas uPAR overexpression increased senescence dra-
matically.
 We have recently elucidated a previously unknown 
role for uPAR in the regulation of UPS with critical ef-
fects on the outcome of cell function  [11] . Accumulating 
evidence indicates that the post-translational modifica-
tion of proteins by ubiquitination followed by their pro-
teasomal degradation regulates key processes of cell 
function. Moreover, these studies suggest that therapeu-
tic agents that target UPS might be of clinical importance 
 [36] . It has been demonstrated that UPS-mediated degra-
dation of transcription and cell survival factors in cardio-
myocytes are upregulated by doxorubicin treatment and 
may contribute to doxorubicin cardiotoxicity  [2, 9] . Our 
findings indicate that in addition to cardiotoxicity, doxo-
rubicin-induced UPS may initiate vascular toxicity via 
induction of cell senescence in VSMC and thus provide 
new insights regarding side effects of anthracyclines in 
anti-cancer therapy. Our results demonstrate that low 
concentrations of doxorubicin affect two main processes 
of UPS in VSMC, namely ubiquitination and proteasom-
al-mediated degradation. This mechanism initiates doxo-
rubicin-induced ubiquitination and proteasomal degra-
dation of TRF2 that culminates in VSMC senescence. 
 Hodjat/Haller/Dumler/Kiyan
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Abstract 
 
 DNA damage induced by numerous exogenous or endogenous factors may have 
irreversible consequences for the cell. The DNA damage response (DDR) is powerful 
signaling machinery triggered in response to DNA damage, to provide DNA damage 
recognition, signaling and repair. DDR is a highly coordinated mechanism involving 
posttranslational changes of repair proteins, their recruitment onto DNA damage foci followed 
by disassembly and protein degradation. The precise knowledge of the molecular mechanisms 
determining DNA foci formation, resolution and related signaling remains, however, elusive. 
In this study, we identified the multifunctional urokinase receptor (uPAR) as a novel factor 
that determines DDR of different cell types, such as primary human and murine vascular 
smooth muscle cells (VSMC) and MDA-MB 231 cancer cell line. We observed that uPAR-
deficient cells are sensitized to DNA damage and reveal a decreased survival as a result of 
impaired DNA repair. We found that the underlying pathways involve uPAR-mediated 
regulation of the proteasome subunit Rpn7 and its redistribution to DNA damage foci. We 
further show that Rpn7 nuclear translocation requires Rpn7 association with the tyrosine 
kinase c-Abl. We provide evidence that nuclear c-Abl associates with the tyrosine 
phosphatase SHP-2, which undergoes acetylation and serves for regulation of DNA repair. 
Our findings demonstrate an unusual but common, cell type independent uPAR-directed 
mechanism utilized by cells to modulate DDR and optimize cellular response to DNA 
damage. 
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Introduction 
 
 Genomic instability resulting from damaged DNA causes many diseases such as 
cancer, cardiovascular and neurodegenerative disorders, immune deficiencies and metabolic 
syndrome(Jackson and Bartek, 2009). Both exogenous factors like ultraviolet light, ionizing 
radiation, environmental chemicals and endogenous sources like reactive oxygen species can 
induce DNA damage. Moreover, many drugs used to treat cancer, psoriasis, and some other 
disorders have been identified as DNA-damaging agents (Espinosa et al., 2003; Lebwohl et 
al., 2005). To combat DNA damage, cells evolved the DNA damage response (DDR), which 
represents highly coordinated signaling mechanisms aiming at recognition DNA lesions, 
signaling their appearance, and providing efficient repair. Deficiency and failures in DDR 
mechanisms lead to increased cell sensitivity to DNA-damaging factors. Though DDR 
involves a wide range of cellular events, which are regulated at different molecular and 
cellular levels, many of these pathways occur by a common program in response to different 
classes of DNA lesions. The main molecular mechanisms underlying DDR are changes in 
transcriptional control and posttranslational modifications (Jackson and Bartek, 2009). Recent 
studies have revealed that the ubiquitin-dependent proteasomal degradation system (UPS) is 
essential to coordinate DDR after DNA damage (Ramadan and Meerang, 2011). A growing 
body of evidence indicates that UPS is indispensable to mediate and tightly control 
disassembly, removal, and degradation of DDR proteins recruited to DNA lesions such as 
DNA double strand breaks (DSB). Data coming from genetic, biochemical and biological 
approaches propose the UPS as a central element in the DDR orchestration at the sites of 
DSB. They further suggest the major proteasome assembly, the 26S proteasome as a 
constitutive and conserved part of the DSB repair mechanism (Jung et al., 2009; Ramadan and 
Meerang, 2011). The 26S proteasome predominantly mediates the second step of the UPS-
directed proteolysis, namely degradation of ubiquitinated proteins. The 26S proteasome 
consists of the 19S regulatory particles and the 20S catalytic core particle with protease 
activity. Molecular organization and assembly of 26S proteasome subunits are crucial for 
regulation of proteasomal activity (Ranek and Wang, 2009). How functional properties of 26S 
proteasome are regulated and orchestrated upon DDR remains, however, poorly explored. 
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 The multifunctional urokinase (uPA)/urokinase receptor (uPAR) system plays a central 
role in the molecular events coordinating functional behavior and cell fate in health and 
disease (Binder et al., 2007; Pillay et al., 2006). Though uPA/uPAR interference with DDR 
has not been proved experimentally, several clues from different studies suggest that 
uPA/uPAR might also be involved in at least some pathways triggered by DNA damage. 
Thus, in different cell types this system regulates main cellular functions related to DDR, such 
as proliferation, cell cycle, senescence, and apoptosis (Blasi and Carmeliet, 2002; Smith and 
Marshall, 2010). Others and we have demonstrated recently that uPAR possesses 
transcriptional activity and may undergo nuclear translocation and regulate cellular events at 
nuclear level that further strengthens uPAR implication in DDR-related processes (Asuthkar 
et al., 2012; Kiyan et al., 2012). Our recent studies revealed one novel function for uPAR, 
which may be additionally relevant to DDR mechanisms. We found that uPAR deficiency 
resulted in decreased proteasomal activity in tissues of uPAR-/- mice and that uPAR mediates 
specific ubiquitination and proteasomal degradation of proteins determining cell functional 
behavior (Hodjat et al., 2012; Kiyan et al., 2012). In the present study we demonstrate that 
uPAR serves as an active participant in DDR signaling events in a general, cell type 
independent fashion. uPAR-deficient cancer and smooth muscle cells are sensitized to DNA 
damage and reveal decreased survival as a result of impaired DNA repair. Consistent with our 
previous observations, we further show that underlying pathways involve uPAR-mediated 
regulation of the 26S proteasome subunit Rpn7 and the tyrosine phosphatase SHP-2. We 
provide evidence for a critical role of the tyrosine kinase c-Abl in these processes. 
 
 
Results 
 
uPAR downregulation affects activation of DDR proteins 
 To get a first evidence for uPAR interference with DDR, we analyzed main marker 
proteins involved in DDR, such as checkpoint kinase 2 (Chk-2) and -histone 2 (H2AX). To 
induce DNA damage, cells were treated with H2O2 for different periods of time. We used 
VSMC isolated from uPAR-deficient mice and human MDA-MB cells where uPAR 
downregulation was effectively achieved by nuclefection with the corresponding siRNA. 
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Activation of Chk-2 and H2AX was monitored by their phosphorylation in response to H2O2. 
For both cell types we observed that already basal phosphorylation of these proteins was 
significantly increased in uPAR-deficient cells. Correspondingly, activation of Chk-2 and 
H2AX in response to H2O2 in cells lacking uPAR, though being reliable, was less effective 
than in control cells thus pointing to uPAR requirement for properly regulated DDR process 
(Fig. 1A-D). Similar data were obtained for human VSMC with downregulated uPAR (data 
not shown). 
 To further confirm these observations, we performed immunocytochemical studies. In 
agreement with the biochemical data, uPAR-deficient cells revealed higher basal level for 
phosphorylated Chk-2, H2AX, and ataxia talengiectasia mutated (ATM) kinase and showed 
deregulated response to DNA damage compared to control cells (Fig. 1E,F, shown for human 
VSMC; similar effects for MDA-MB cells not shown). 
 
uPAR-deficient cells reveal decreased survival and impaired DNA repair 
 To elucidate potential function for uPAR in DDR related signaling and cell fate, we 
examined cell death sensitivity to DNA damage in cells with downregulated uPAR. Cell 
survival was documented 24 hrs after H2O2 treatment. Apoptotic cell death was quantified 
using Cell Death Elisa kit (Roche). We found that both VSMC and MDA-MB cells lacking 
uPAR were much less resistant to DNA damage and revealed impaired survival (Fig. 2A) and 
significantly increased cell death (Fig. 2B). To analyze whether these functional changes may 
result from accumulated damaged DNA in uPAR-deficient cells, single cell gel 
electrophoresis assay (comet assay) was performed. Comet tail moment reflecting the number 
of DNA breaks was calculated 4 hrs after inducing DNA damage. We observed that uPAR 
deficiency independently of cell type indeed lead to delayed DNA repair (Fig. 2C-E). 
 
uPAR mediates intracellular redistribution of the proteasomal subunit Rpn7 and its 
recruitment to DDR foci 
 Based on the aforementioned critical role of UPS in DDR and on our recent findings 
demonstrating uPAR ability to control at least some of UPS functions, we next tested whether 
the observed sensitization of uPARsi cells to DNA damage and impaired DNA repair in these 
cells might be related, at least in part, to UPS deregulation. Pilot experiments based on 
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proteasome purification by immunoprecipitation followed by mass spectrometry of selected 
bands revealed deregulation of the Rpn7 regulatory particle in uPARsi cells subjected to DNA 
damage (data not shown). Rpn7 is known to stabilize DNA damage foci upon genotoxic stress 
(Tsolou et al., 2012) and therefore we next explored Rpn7 intracellular distribution and 
recruitment to DDR foci in uPAR-deficient and control cells. Indeed, we observed that in 
control cells subjected to DNA damage Rpn7 revealed effective translocation to cell nucleus, 
recruitment to foci and colocalization with phosphorylated ATM, a major component of DNA 
damage foci. In contrast, these processes were significantly impaired in cells with 
downregulated uPAR (Fig. 3A-C). In uPAR-silenced cells Rpn7 revealed some nuclear 
staining already in the absence of any treatment and DNA-damaging challenge did not 
significantly increase Rpn7 nuclear redistribution any further. This was even more 
pronounced in VSMC from uPAR-/- mice (Fig. 3B,C). To substantiate results of our 
immunocytochemical studies, we performed cell fractionation and determined Rpn7 in 
nuclear fractions. As shown in Fig. 3C, the results of these biochemical experiments were in a 
good agreement with those of immunocytochemistry pointing to uPAR requirement for a 
functional Rpn7 response to DNA damage. 
 
c-Abl tyrosine kinase is required for uPAR-dependent Rpn7 nuclear import 
 uPAR is a multifunctional receptor interacting with diverse transmembrane and 
nuclear signaling proteins to trigger and propagate numerous signaling cascades (Smith and 
Marshall, 2010). We were next interested in elucidating specific signaling pathways mediating 
uPAR-dependent Rpn7 nuclear import and recruitment to DNA damage foci. Several recent 
reports point to an important role in DDR for the non-receptor tyrosine kinase c-Abl, which 
undergoes strong activation in response to various stimuli including DNA damage (Maiani et 
al., 2011; Wang et al., 2011). To verify our hypothesis implying a possible involvement of c-
Abl in the observed effects, we performed c-Abl inhibition using its specific inhibitor 
imatinib. Rpn7 nuclear redistribution in response to DNA damage was strongly inhibited by 
this treatment independently of cell type providing clear evidence for c-Abl necessity in DDR-
related Rpn7 nuclear import (Fig. 4A). To gain further insight into c-Abl interference with 
Rpn7 upon DNA damage, we performed several rounds of immunoprecipitations. Similar to 
the previous experimental settings, both VSMC and cancer cells subjected to DNA damage 
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were used. We found that c-Abl was effectively co-precipitated with Rpn7 in control cells and 
that DNA damage stimulated this reversible association. In uPAR-deficient cells Rpn7 
association with c-Abl was much less pronounced and no impact of DNA damage on this 
association was found (Fig. 4B). We also observed that c-Abl phosphorylation on tyrosine 
residues in response to DNA-damaging signal was abolished by loss of uPAR (Fig. 4C). c-Abl 
is known to serve as a cytoplasmic-nuclear shuttle protein and its cellular redistribution is 
related to functional activity (Gonfloni et al., 2012). In cell fractionation experiments we 
found that within 60 min of DNA-damaging treatment c-Abl was enriched in nuclear fraction 
of control but not uPAR-deficient cells (Fig. 4D,E). 
 
The tyrosine phosphatase SHP-2 associates with c-Abl and is involved in the uPAR-dependent 
DNA repair  
 c-Abl is a Src homology (SH) 2 and SH3 domain-containing tyrosine kinase. This 
structure enables c-Abl interaction and association with a number of signaling and repair 
proteins implying complex roles for c-Abl in DDR (Shaul and Ben-Yehoyada, 2005). Several 
recent studies provide evidence for a functional interference of c-Abl and the tyrosine 
phosphatase SHP-2, which is a natural substrate for c-Abl, induced by the DNA damage 
(Yuan et al., 2005; Yuan et al., 2003). We have demonstrated previously that SHP-2 plays an 
important role controlling uPAR-dependent signaling and functions in human VSMC (Kiyan 
et al., 2009). It was therefore tempting to suppose that c-Abl, beyond regulation of Rpn7, 
might mediate further uPAR-dependent cellular pathways upon DNA damage, such as those 
related to SHP-2. Indeed, we found in our immunoprecipitation experiments that c-Abl was 
associated in nuclear fractions with SHP-2 in uPAR- and DNA damage- dependent fashion 
(Fig. 5A). To define a potential contribution of SHP-2 to uPAR-directed and c-Abl-dependent 
DDR mechanisms, we examined SHP-2 activation in response to DNA damage in uPAR-
lacking and control cells and functional consequences of SHP-2 deficiency for DNA repair. 
As expected, we observed pronounced, time-dependent SHP-2 activation in control cells 
subjected to DNA damage. However, in uPAR-deficient cells level of phosphorylated SHP-2 
was negligible and showed no change after DNA damaging treatment (Fig. 5B). Efficient 
DNA repair pathways require different post-translational modifications at lysine residues of 
histone and non-histone proteins, such as acetylation, methylation, ubiquitination and 
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SUMOylation (Chatterjee et al., 2012). We asked whether SHP-2 might undergo beyond 
tyrosine phosphorylation any further post-translational modification in response to DNA 
damage. We observed that DNA-damaging cell treatment induced strong acetylation of SHP-2 
(Fig. 5C). This effect has not been reported so far. Even more interesting was the observation 
that SHP-2 acetylation was an uPAR- and c-Abl-dependent process (Fig. 5D). Cell 
fractionation experiments revealed that only nuclear, but not cytoplasmic SHP-2 underwent 
acetylation upon DNA damage (Fig. 5E). To explore functional consequences of SHP-2 for 
cell functional behavior upon DNA damage, we relied again on DNA repair comet assay 
using control cells and cells with downregulated SHP-2. These experiments demonstrated that 
cells lacking SHP-2 were much less resistant to DNA damage and revealed a delayed DNA 
repair (Fig. 5F). 
 
 
Discusion 
 
 The DDR network plays a cardinal role in the maintenance of genome integrity and is, 
as one of the key cellular mechanisms, a subject of intensive research. Most of these studies 
are focused on the coordinated mechanisms by which DDR proteins orchestrate at the site of 
DNA damage. Molecular mechanisms providing sensing and transduction of DNA-damaging 
signals from receptors to DDR effectors remain, however, largely unknown. Our study 
provides compelling evidence for the role of uPAR in regulation of signaling mechanisms 
underlying DDR. We show that uPAR serves as a cellular sensor for DNA-damaging signal 
and that loss of uPAR sensitizes cells to DNA damage and retards DNA repair. The 
underlying mechanism suggests uPAR-mediated regulation of the proteasomal subunit Rpn7 
and the tyrosine phosphatase SHP-2 via the c-Abl tyrosine kinase (Fig.6). 
 The uPA/uPAR is a surprisingly multifaceted system upregulated upon numerous 
diseases, primarily those related to inflammation, tissue remodeling and cancer (Binder et al., 
2007; Blasi and Carmeliet, 2002; Pillay et al., 2006). uPAR realizes two important cellular 
functions providing regulation of extracellular proteolytic cascade and serving as a signaling 
receptor to promote changes in cell functional behavior (Smith and Marshall, 2010). The 
uPAR-directed signaling can occur via uPA-uPAR binding or be uPA-independent. As a GPI-
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anchored receptor lacking transmembrane and intracellular domains, uPAR associates with 
transmembrane proteins, such as integrins, tyrosine kinase receptors and others, to initiate 
signal transduction. Multiple signaling cascades induced via these co-receptor cooperations 
have been identified over the last decade (Blasi and Carmeliet, 2002). Though many advances 
have been done in the field, the mechanisms of uPAR signaling are still not completely clear 
and several controversies remain. At the level of cellular functions determining the cell fate in 
response to microenvironment, uPAR-directed signaling is believed to regulate physiological 
and pathophysiological conditions requiring changes in cell proliferation, migration, adhesion, 
and survival (Pillay et al., 2006). Due to these multifunctional properties uPAR presents many 
opportunities to be utilized as a target for specific therapies in diverse human diseases. 
However, none of the earlier studies has addressed possible involvement of uPAR in response 
to DNA damage that is a key event in cancer, aging, ischaemia-reperfusion injury, 
inflammatory, viral and other disorders. 
 To analyze uPAR necessity for DDR, we used a cellular model based on uPAR 
downregulation by means of siRNA in human primary VSMC and in human cancer cell line, 
as well as uPAR-deficient mouse VSMC. Our data show that uPAR deficiency in both cell 
types resulted in increased cell sensitization to DNA damage and impaired DNA repair. This 
function for uPAR has not been reported before. One recent study related to this issue has 
shown that transcriptional silencing of metalloproteinase 9 in combination with 
uPAR/cathepsin B affected DSB repair machinery in human glioma in vitro and in vivo 
(Ponnala et al., 2011). One further report from the same group suggested that inhibition of 
uPAR together with cathepsin B might be used in radiation therapy to target glioma-initiating 
cells. Similar to our observations, authors found changes in H2AX expression and 
functionality of H2AX foci after uPAR/cathepsin B downregulation (Malla et al., 2012). 
However, the impact of uPAR on DDR-related mechanisms independently of cathepsin B was 
not explored in those studies. 
 We show that the c-Abl non-receptor tyrosine kinase is required to mediate uPAR-
related responses to DNA damage. The c-Abl tyrosine kinase is implicated in diverse cellular 
activities including growth factor signaling, cell adhesion, oxidative stress, and DNA damage 
response (Gonfloni et al., 2012). The essential role for c-Abl in molecular mechanisms and 
cellular responses underlying DDR has been implicated by several studies. c-Abl is known to 
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control pro-apoptotic signals via interference with ATM, p73 and p53 (Yuan et al., 1999). 
Recent studies demonstrate that c-Abl deficiency resulted in a broad spectrum of defects in 
cell response to genotoxic stress, such as activation of Chk1, Chk2 and p53, nuclear foci 
formation, and DNA repair (Wang et al., 2011). It was proposed that multifunctional c-Abl 
signaling might mediate the molecular events at the interface between stress signaling, 
metabolic regulation, and DNA damage (Gonfloni et al., 2012). Our study adds new aspects 
into proposed models of c-Abl involvement in the DDR. Our findings suggest that c-Abl may 
orchestrate two uPAR-dependent cellular events in response to DNA damage, namely nuclear 
import of the Rpn7 proteasomal subunit and acetylation of the tyrosine phosphatase SHP-2. 
These data are along earlier observations of others showing that c-Abl acts in concert with 
tyrosine kinase receptors, such as VEGFR, PDGFR, FGFR and others (Anselmi et al., 2012.; 
Frasca et al., 2007; Li et al., 2001; Srinivasan et al., 2009). We have shown previously that 
PDGFR serves as a transmembrane co-receptor for uPAR to realize uPAR-directed 
intracellular signaling (Kiyan et al., 2005). Therefore, a scenario may be suggested that the 
cell-surface uPAR senses a DNA-damaging signal, associates with PDGFR and induces c-Abl 
activation. Alternatively, uPAR might first undergo internalization and then initiate c-Abl 
activation and cellular redistribution. It was shown that both mechanisms might be utilized by 
other membrane receptors, such as tyrosine kinase receptor to modulate DDR via multiple 
pathways (Squatrito and Holland, 2011). 
 Our findings strengthen a novel function for uPAR documented in our recent reports 
and classify uPAR is an important regulator of intracellular proteolysis controlling 
ubiquitination and proteasomal degradation of proteins determining cell functional behavior. 
We found that loss of uPAR resulted in deregulation of the 26S proteasome subunit Rpn7, 
which is an integral component of DDR. What further components of UPS might be regulated 
by uPAR is a question of great importance that may have an impact in the development of 
new therapeutic strategies aiming at uPAR targeting. 
 
Materials and Methods 
Cell culture, cell nucleofection and treatment with H2O2 
Human primary umbilical artery VSMC were isolated from umbilical artery using 
explant technique in VascuLife SMC cell culture medium (CellSystems® Biotechnologie 
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Vertrieb GmbH, St. Katharinen, Germany). The procedure conforms to the Declaration of 
Helsinki and was approved by the local ethics committee. After 1st passage fibroblasts were 
removed from the culture by cell separation using monoclonal anti-fibroblasts antibodies 
(anti-CD90, Dianova) and magnetic Dynabeads® Goat anti-Mouse IgG (Invitrogen). VSMC 
were used between passages 2-4. Aortic VSMC were isolated from male uPAR-/- mice and 
uPAR+/+ (wild type) mice as controls (all on C57/BL6 background, age 10-12 weeks). All 
mice experiments were carried out according to the European Commission guidelines and 
were approved by the ethics committee of Hannover Medical School. Animals were 
euthanized by iv injection of 200 µl 2% avertin solution. The aortas were dissected, cut into 
1–2 mm on a side pieces and subjected to enzymatic digestion as described (Fallier-Becker et 
al., 1990). VSMC were cultivated in DMEM (Dulbecco’s modified Eagle’s medium) 
supplemented with 10% (v/v) fetal bovine serum. MDA-MB 231 human breast cancer cell 
line (American Type Culture Collection, Rockville, MD) were cultured in Dulbecco's 
modified Eagle's medium (DMEM, Lonza) supplemented with 10% fetal bovine serum 
(PromoCell GmbH). 
 DDR pathway activation was induced by cell treatment with 100 µM H2O2 at 37°C. 
For Comet assay cells were treated with 5mM H2O2 for 20 min on ice. 
Small interfering RNAs (siRNAs) for downregulation of uPAR, SHP-2, and control 
silencing RNA were obtained from Santa Cruz Biotechnology and were transfected to the 
human UASMC using Amaxa Nucleofector
TM
 (Lonza). Basic Primary Smooth Muscle cell 
nucleofector kit (Lonza) was used according to the manufacturer’s instructions. Cell Line 
Nucleofector® Kit V (Lonza) was used for MDA-MB231 nucleofection. Efficiency of 
nucleofection was routinely evaluated by western blotting 24-72 hrs after cell nucleofection. 
 
Immunostaining 
Cells grown on coverslips were fixed by addition of 10% formaldehyde to the final 
concentration of 2%, permeabilized in 0.1% Triton X-100 for 10 min and blocked with 3% 
(w/v) BSA/PBS at 4°C overnight. Cells were labeled with primary and corresponding Alexa 
Fluor® 488- or Alexa Fluor® 594-conjugated secondary antibody (Invitrogen) for 1 h at room 
temperature. Cells were then mounted with Aqua-Poly-Mount mounting medium 
(Polysciences) and analyzed on a Leica TCS-SP2 AOBS confocal microscope. For 
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immunostaining of mice Aortic VSMC, cells were incubated with 5% mouse serum in PBS 
followed by 1h incubation with 5% normal goat serum. 
 
Preparation of cell lysates, Immunoprecipitation and Western Blotting  
Cultured cells were lysed in RIPA buffer containing 1mM PMSF, 1 mg/ml aprotinin, 1 
mg/ml leupeptin, 1mM Na3VO4, 1mM NaF and incubated for 10 min at 4°C. For whole cell 
lysate preparation lysates were subjected to sonication. The lysates were centrifuged at 10000 
rpm for 10 min. For immunoprecipitatin 600 μg total cell lysate with 4 μg of specific 
antibodies was used. After 3 hours immunocomplexes were precipitated with A/G PLUS-
agarose beads. Precipitates were washed 3 times in PBS buffer containing protease inhibitors 
and subjected to SDS-electrophoresis. 
Isolation of cytosolic and nuclear fractions was performed as described (Suzuki et al., 
2010). 
Antibodies against P-Chk2, H2AX, Phospho-ATM, Phospho-SHP-2, SHP-2, Ac-Lys, 
c-Abl, Histon H3 were from Cell Signaling. Anti-tubulin antibody was from BD 
Pharmingen™. Alexa Fluor 488-conjugated chicken anti-rabbit antibody and Alexa Fluor 
594-conjugated donkey anti-mouse antibody were from Invitrogen. 
 
Comet assay 
 Comet assay was performed using OxiSelect™ Comet Assay Kit from Cell Biolabs, 
Inc. according to the manufacturer's instructions. 
 
Cell death analysis 
 Apoptotic cell death was analyzed by Cell Death Detection ELISA
PLUS 
from Roche 
Applied Scince accordingly to the manufacturer's instructions. 
 
Statistical analysis 
All experiments were performed at least three times. Statistical significance analysis 
(P<0.05) was performed using a Student’s t test. “*” represents statistically significant 
differences at P<0.05. 
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Figure legends 
Figure 1. uPAR deficiency deregulates DDR pathway activation. A. VSMC isolated from 
WT and uPAR-/- mice were treated with 100 µM H2O2 for indicated time. Phosphorylation of 
Chk-2 and H2AX was assessed by western blotting. B. Kinetics of H2O2 -induced Chk-2 and 
H2AX phosphorylation in WT and uPAR-/- mouse VSMC. Tubulin was used for 
normalization. C. WT and uPAR-/- mouse VSMC were treated with H2O2 for 1 h, then fixed 
and stained for P-Chk-2 (Alexa 488) and P-ATM (Alexa 594). D. Cells treated as in C were 
stained for H2AX (Alexa 488) and P-ATM (Alexa 594). 
 
Figure 2. uPAR deficiency delays DNA repair and sensitizes cells to DNA damage. A. 
SiCo and uPARsi -nucleofected human VSMC were treated with 5mM H2O2 for 20 min on ice 
to induce DNA damage. Right and left panels show comet tails of SiCo and uPARsi VSMC 
after 4 hrs of DNA repair visualizes by Vista Green DNA staining. Comet tails of 
nucleofected human VSMC (B) and WT and uPAT-/- mouse VSMC (C) were quantified as 
described in the Materials and Methods. D. SiCo and uPARsi-nucleofected human VSMC 
were treated with different concentrations of H2O2 for 20 min on ice to induce DNA damage. 
The number of viable cells was calculated 24 hrs after DNA damage. C. SiCo and uPARsi-
nucleofected human VSMC were treated with H2O2 as indicated to induce DNA damage. Cell 
apoptosis was detected 24 hrs after DNA damage using Cell Death Elisa Kit (Roche). 
 
Figure 3. uPAR is essential for DNA damage-induced Rpn7 nuclear import. SiCo and 
uPARsi -nucleofected human VSMC were treated with 100µM H2O2 for 1 h at 37°C. Then 
cells were fixed and stained for Rpn7 (Alexa 488) and P-ATM( Alexa 594). The lower panels 
show indicated area with higher magnification. B. WT and uPAR-/- mouse VSMC were 
treated with 100µM H2O2 for 1 h at 37°C. Then cells were fixed and stained for Rpn7 (Alexa 
488) and P-ATM( Alexa 594). H2O2 -induced Rpn7 content in nuclear fraction was assessed 
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after subcellular fractionation of SiCo- and uPARsi-nucleofected human VSMC and WT and 
uPAR-/- mouse VSMC. Histon H3 was used as loading control. 
 
Figure 4. c-Abl kinase is required for DNA damage-induced Rpn7 nuclear import. 
MDA-MB 231 cells were pretreated with 2 µM imatinib for 1 hr at 37°C prior to H2O2 
stimulation. After stimulation with 100 µM H2O2 for 1 h cells were fixed and stained for Rpn7 
(Alexa 488) and P-ATM( Alexa 594). B. H2O2 -induced association of Rpn7 and c-Abl in WT 
and uPAR-/- VSMC was studied using co-immunoprecipitation from whole cell lysate. C. 
H2O2 -induced c-Abl phosphorylation in WT and uPAR-/- VSMC was studied using 
immunoprecipitation from whole cell lysate. D. WT and uPAR-/- mouse VSMC were treated 
with 100µM H2O2 for 1 h at 37°C. Then cells were fixed and stained for c-Abl (Alexa 488) 
and P-ATM( Alexa 594). E. H2O2 -induced Rpn7 content in nuclear fraction was assessed 
after subcellular fractionation of WT and uPAR-/- mouse VSMC. Histon H3 was used as 
loading control. 
 
Figure 5. SHP-2 is involved in uPAR- and c-Abl-related DDR. A. H2O2 -induced 
association of c-Abl and SHP-2 in WT and uPAR-/- VSMC was studied using co-
immunoprecipitation from cytosolic and nuclear fractions. The lower panels show loading 
control and purity of both, cytosolic and nuclear fractions. B. H2O2 -induced SHP-2 
phosphorylation in WT and uPAR-/- VSMC (upper panel) and SiCo- and uPARsi-
nucleofected human VSMC (lower panel) was assessed by western blotting from whole cell 
lysate. Tubulin shows loading control. C. H2O2 -induced SHP-2 acetylation was assessed by 
immunoprecipitation from whole cells lysate. D. H2O2 -induced SHP-2 acetylation in SiCo- 
and uPARsi-nucleofected human VSMC and in cells pre-treated with 2 µM imatinib prior to 
H2O2 stimulation was assessed by immunoprecipitation from whole cell lysate. E. H2O2 -
induced SHP-2 acetylation was assessed by immunoprecipitation from cytosolic and nuclear 
fractions. F. SiCo- and SHP-2si-nucleofected human VSMC were treated with 5 mM H2O2 for 
5 min on ice to induce DNA damage. Comet assay was performed 4 hrs after H2O2 treatment. 
Tail moments were quantified as described in Material and Methods. 
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Figure 6. Schematic presentation of uPAR-mediated DDR pathway regulation. DNA 
damaging drugs induce activation of cytosolic c-Abl and its association with Rpn7. Rpn7 and 
c-Abl undergo nuclear translocation and are recruited to the DDR foci. Nuclear c-Abl is 
essential for DDR-induced SHP-2 phosphorylation and acetylation. Loss of uPAR interferes 
with c-Abl activation and nuclear import and thus compromises DNA repair. 
 
                                                                                                      
                                                                                                                                                           
 58 
 
                                                                                                      
                                                                                                                                                           
 59 
 
 
 
 
 
 
 
 
 
 
                                                                                                      
                                                                                                                                                           
 60 
 
 
 
 
                                                                                                      
                                                                                                                                                           
 61 
 
 
                                                                                                      
                                                                                                                                                           
 62 
 
 
 
 
                                                                                                      
                                                                                                                                                           
 63 
 
 
 
 
 
 
 
 
 
 
                                                                                                      
                                                                                                                                                           
 64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             4. Discussion 
                                                                                                      
                                                                                                                           Discussion                                                    
 65 
Maintenance of genome integrity is the critical mission of all living cells that constantly 
exposed to different endogenous and exogenous DNA damaging agents. For this aim a 
complex well coordinated network of mechanisms are evolved that prevents genomic 
instability towards such inevitable and constant threats. DNA damage response is a signal 
transduction process that has the ability to sense, transduce and repair DNA damage at the site 
of injury. In case of impairment or inability of repair mechanism, DDR may trigger 
mechanisms based on type and location of DNA lesion that shift the cell fate towards 
senescence and apoptosis. These complex processes require crucial function of many 
regulators orchestrating different signaling pathways. 
uPAR is a multifunctional receptor that besides its well known role in pericellular proteolysis 
is involved in a wide range of intracellular signaling processes during cell migration, invasion 
and proliferation. So far many studies have been performed to elucidate uPAR diverse roles in 
cell physiology and still a lot remains to be discovered about the underlying mechanisms.  
In the present doctoral project we provided novel evidences for uPAR-mediated regulation of 
DDR during DNA repair mechanism and cell senescence as an important consequence of 
DNA damage. Our study focused mainly on UPS and its regulatory role in DDR-directed 
cellular events. As an experimental approach to down- and up-regulation of uPAR expression, 
we used small interfering RNA combined with the lentiviral cell infection or with cell 
nucleofection. In addition we used cells isolated from the uPAR-deficient mice. 
Manuscript 1: 
Telomeres, the ends part of chromosomes, have a specialized chromatin structure to protect 
chromosome ends from being recognized as double-stranded DNA breaks. It is reported that 
damage to telomere structure might be irreparable and contribute to telomere dysfunction that 
induces DNA damage response towards senescence or apoptosis [85]. The irreparability of 
telomeric tracts may be the consequence of their functions in preventing chromosomal 
fusions. Though many efforts have been made to elucidate the mechanism of DNA damage 
response, still not much is known about the DDR related telomeric regions of genome.    
TRF1 and TRF2 are the critical components of functional telomere that interact directly with 
double stranded telomeric DNA. Specifically, TRF2 is responsible for the formation and 
maintenance of shelterin structure. Numerous studies demonstrated the result of telomere 
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uncapping by interference with TRF2 expression that contributes to telomere dysfunction and 
cell senescence [105, 107, 146]. In our study we showed that low doses of the anti-cancer 
drug Doxorubicin (DOX) induced senescence in VSMC that was accompanied by decrease in 
TRF2 protein level. We showed further that TRF2 regulation was a hallmark of senescence 
response in DOX treated cell. TRF2 downregulation by means of siRNA induced cell 
senescence in normal and DOX treated cells, that was abrogated in our replenishing 
experiments. Our data confirm the impact of TRF2 regulation on activation of DDR-related 
pathways towards senescence.  
In this thesis we reported for the first time the role for multifunctional receptor uPAR in 
controlling telomere function during senescence response. The involvement of uPA system in 
cellular senescence has been previously discussed. A more than 50-fold increase in uPA 
activity was reported in senescent endothelial and fibroblast cells [147, 148]. PAI-1, the 
inhibitory member of uPA/uPAR system, was shown to be an essential mediator of replicative 
senescence leading to down-regulation of PI(3)K–PKB signalling and nuclear exclusion of 
cyclin D1 [149]. Also the increased uPAR expression was associated with senescence-
associated secretory phenotype in different cell lines [150].  
Our data based on in vivo and in vitro targeting of uPAR suggested that uPAR is an active 
regulator of cellular senescence in VSMC. 
DNA-damaging drug, Doxorubicin, is one of the most effective antitumor agents, though 
DOX application is limited due to its cardiotoxic effect. Our data suggested that in addition to 
cardiomyocytes, DOX also affect VSMC via induction of senescence that contributes to 
vascular dysfunction. Our present finding provides novel evidence for the vascular toxicity 
side effect of DOX and the underlying mechanisms.  
We reported that genotoxic drug DOX enhances TRF2 degradation via affecting two main 
processes of the UPS mechanisms, namely TRF2 ubiquitination and proteasomal degradation. 
These data are in agreement with the previously known role of DOX in activation of UPS in 
other cell types that results in degradation of many transcriptional and survival proteins [151]. 
Importantly we showed that uPAR is a key regulatory factor required in both processes of 
ubiquitination and proteasomal degradation.  
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Ubiquitination is a multi-step process, accomplished by the concerted, well organized action 
of different enzymes. E3 ubiquitin ligases are a large family of proteins that are engaged in 
transfer of ubiquitin to a substrate protein. SIAH1 is an E3 ubiquitin ligase whose role in 
direct ubiquitination of TRF2 via p53 pathway during replicative senescence has been 
recently discussed. In this thesis project we observed the activation of P53/ Siha1 pathway in 
DOX treated cells. Our results further evidenced that uPAR was required for TRF2 
ubiquitination. Whether or not uPAR is involved in regulation of other enzymes of 
ubiquitination apparatus remains to be elucidated. Clearly, further research is required to 
identify the mechanisms by which uPAR can affect TRF2 ubiquitination. A role for 
deubiqutinating enzymes on TRF2 degradation is still unclear. 
26S proteasome  is the chief site of regulatory protein turnover in cell. Its regulatory role in 
DDR in both protein turnover and protein recruitment has been well defined. In our present 
project we showed that TRF2 serves as a substrate for proteasomal degradation in DDR-
related senescence. We found that uPAR silencing abrogated DOX-induced proteasomal 
activity in human cells and in VSMC from uPAR-deficient mice. The data suggest a novel 
regulatory role for uPAR in proteasome activity that is essential for control of telomere 
function during senescence. In order to elucidate how uPAR may affect proteasome activity, 
we performed further experiments (the data are presented and discussed below in 
supplementary parts). 
Overall, our findings suggest that uPAR might have multiple functions in regulation of not 
only cell surface related but also intracellular proteolysis. 
 
Manuscript 2:  
 
Precise regulation of DNA damage response is crucial for cellular survival after DNA 
damage, and its abrogation often results in genomic instability contributing to cell apoptosis 
or cancer. Over last decades large efforts have been performed to improve knowledge in DDR 
area that have introduced several key molecules and regulatory mechanisms of signaling 
initiation and transduction that was unknown before.  
Among all regulatory molecules, the components of ubiquitin proteasomal system known to 
play cardinal roles in many aspects of DNA damage repair mechanism in formation of DNA 
foci, resolution and related subsequent signaling [152, 153]. 26S Proteasomal, a highly 
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conserved member of UPS has recently attracted many research interests.  It involves not only 
in protein turnover but has also non-proteolytic functions in protein recruitment of DNA 
repair factors [152]. Many ubiquitinated proteins are known to bind to the 26S but escape 
proteolysis, only to be deubiquitinated and released [154]. It is reported that individual 
subunits of the 19S have non-proteolytic roles inside the nucleus and can be recruited to 
specific gene promoters in various eukaryotes [155].  Elucidating the regulatory mechanisms 
of 26S proteasomal components is of particular interest and still not much known about it.  
In the first part of this doctoral project we revealed one novel function for uPAR in DDR 
mechanisms that mediates specific ubiquitination and proteasomal degradation of proteins 
determining cell functional behavior towards senescence. Accordingly, in the second part of 
our research we asked whether uPAR could also be involved in DNA repair mechanisms 
based on its regulatory role on UPS. We applied a model to induce a repairable DNA damage 
response in different cell type. DDR foci are intracellular structures where DDR signalling 
originates. It includes a high local concentration of DDR factors at damage sites providing a 
specific set of markers for the detection of an activated DDR.  The foci detection in our 
experimental model revealed position of the DNA lesions, which was resolved after repair 
mechanisms. 
Our data showed that during DNA damage the proteasome subunit Rpn7 translocates from 
cytosol to the nucleus and be recruited to DNA damage foci.  
High mobility of 26S proteasome is a critical property of the proteasome. Mutant cells, whose 
proteasomes do not efficiently accumulate in the nucleus, are defective in DNA damage repair 
[156]. Furthermore, cut8 mutants are inefficient in degrading cyclin-B during anaphase [157], 
which occurs in the nucleus. These observations support the idea that proteasomes must move 
and accumulate in the nucleus in order to regulate DNA damage repair that is in accordance 
with our data. 
The mechanism of active translocation of proteasomal core complex and the regulatory 
particles in mammalian cells has been recently discussed.  Using the advantage of the in vitro 
assembly system, it has been shown that proteasome passed the nuclear border in the form of 
an intact preassembled proteasome, the 20S+ particle, which is imported through nuclear pore 
complex. However it is proposed the remainder of the 19S RP subunits may be independently 
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targeted to the nuclear compartment [158]. Many shuttling transport receptors have been 
detected that might be involved in translocation of proteasome complex [158]. 
We showed here that nuclear translocation of Rpn7 a component of 26S requires Rpn7 
association with the tyrosine kinase c-Abl. Indeed c-Abl tyrosine kinase has been widely 
associated with various aspects of the DDR (reviewed in [159]). Long before it was found that 
nuclear localization signal (NLS) containing c-Abl shuttles between cytoplasm and nucleus 
and is involved in carrying molecules in both compartments [160, 161]. These data suggest 
that the nuclear-cytoplasmic shuttling of this tyrosine kinase may play a critical role in the 
regulation of c-Abl biological function upon DDR. In agreement with these studies, our data 
revealed that c-Abl indeed plays a critical role in Rpn7 translocation during DDR. 
We reported that in the absent of uPAR all mobility activities of Rpn7 and c-Abl become 
impaired that leads to the cell inability to repair DNA damages and cells prone to apoptosis. 
We next addressed a possible mechanism of direct involvement of uPAR as a cell surface 
receptor in c-Abl localization and function. C-Abl is a member of the Src family contains 
three domains: SH3, SH2 and Src homology (SH1) domains. These features enable c-Abl to 
interact with many intracellular signalling molecules such as phosphatase SHP-2.  
SHP-2, a tyrosine phosphatase implicated in diverse signaling pathways induced by growth 
factors and cytokines, is also involved in DNA damage triggered signalling and cellular 
responses [162]. It has demonstrated previously that SHP-2 plays an important role in 
controlling uPAR-dependent signalling and functions in human VSMC [43]. Taken together 
all these notions, we supposed that SHP-2 might be a direct mediator between c-Abl and 
uPAR. Our data revealed strong activation of SHP-2 after DNA damage treatment. Also in 
our experiment SHP-2-depleted cells, showed impairment of DNA repair upon induction of 
DNA damage that  support the current findings on cellular significance of SHP-2 involvement 
in DDR pathways and chromatin stability[162, 163]. We found that c-Abl was associated in 
nuclear fractions with SHP-2 in uPAR- and DNA damage-dependent fashion. Additionally, 
we observed that DNA-damaging cell treatment induced strong acetylation of SHP-2 in 
uPAR- and c-Abl dependent fashion. This effect that has not been reported so far suggests a 
role for c-Abl on SHP-2 activation. Whether or not SHP-2 mediates uPAR dependent nuclear 
signalling remains an open question. 
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Finding the precise mechanism of uPAR-directed c-Abl nuclear translocation and significance 
of its interaction with SHP-2 upon DDR requires further intensive studies. 
Discussion on supplementary data 
The 26S proteasome is a protein complex consisting of two parts, the catalytic 20S core 
particle and the 19S regulatory particle composed of ATPase (Rpt) and non-ATPase (Rpn) 
subunits. So far many mechanisms have been proposed for regulation of 26S proteasomal 
activity. 
It is known that assembly and disassembly of the 26S proteasome is a conserved mechanism 
for regulation of proteasomal activity in both yeast and mammalian cell. Posttranslational 
modification of different subunit could also affect proteasomal function. In our project we 
decided to elucidate the possible mechanism of uPAR-mediated proteasomal activity through 
analyzing proteasomal assembly. Our experiments based on proteasome immunoprecipitation 
followed by mass spectrometry revealed that the assemblies of some components of 19S 
regulatory particles to the core proteasome are significantly impaired in DOX treated uPARsi 
cells (Fig S1). The MS data were further verified by immunoblotting (Fig S2).  Our data 
showed that the deregulation of proteasome assembly was mostly pronounced among 19S non 
ATPase particles, particularly Rpn7 and Rpn8. 19S regulatory particles are known to be 
involved in recognizing polyubiquitin-linked proteins, and translocation of substrates into the 
catalytic chamber of the 20S core [164, 165]. Each individual components of the 19S particle 
has its own regulatory role.  Rpn7 is known to be required for the integrity of the 26S 
complex by establishing a correct lid structure [166]. Cells containing the mutant form of 
Rpn7 showed a defect in the assembly/ maintenance of the 26S proteasome.  Rpn7 is also 
necessary for the incorporation/ anchoring of Rpn3 and Rpn12 to the lid that suggests the key 
role of Rpn7 in integrity of the 26S complex [166].  
Our findings showed that in the absence of uPAR the proteasome undergoes changes in 
molecular assembly that might cause for change in its activities. These data suggest that 
uPAR regulate proteasomal activity via interfering with incorporation of specific regulatory 
particle to the proteasomal holoensyme and consequently proteasomal assembly. 
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Although the pivotal role of the proteasome is well established in eukaryotic cells, the 
mechanism of proteasome activity and the assembly mechanism of the 19S regulatory particle 
and 26S holoenzyme are still not fully elucidated. 
Our studies based on cell fractionation assay, showed increased proteasomal activity in 
nucleus after DOX treatment that is inline with resulted degradation of nuclear telomeric 
TRF2 (Fig S4). Increased nuclear proteasome activity requires translocation of proteasome 
complex to the nucleus. Therefore impaired translocation of 26S proteasomal  from cytoplasm 
to the nucleus resulted in deregulation of proteasomal assembly. In support for this view, our 
preliminary experiments showed DOX induces accumulation of Rpn7 in the nucleus that is 
impaired in uPARsi cells accompanied by reduced proteasomal activity (Fig S3). These 
preliminary data might raise the hypothesis that DOX induced proteasomal nuclear activity is 
the result of translocation and assembly of proteasomal components to the nucleus mediated 
by uPAR.  
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Fig S1. Quantitative mass spectrometry of purified 20S proteasome.          
Proteasome and its interacting proteins were co-immunoprecipitated from Sico and uPARsi 
cells treated with doxorubicin (DOX) using antibody against α subunit of 20S core particle. 
Isolated proteins were subjected to ESI-LTQ Orbitrap mass spectrometer (Thermo Fisher 
Scientific) for quantitative analysis. Enrichment factor were calculated for each individual 
peptides as the ratio of normalized intensity of peptide peak to the total input cell extract. a. 
Interaction of non-ATPase subunits of 19S regulatory particles to the proteasome core 
particle. b. Interaction of ATPase subunits of 19S regulatory particles to the proteasome core 
particle. Interaction of regulatory proteins to the proteasome core particle. Interaction of Rpn7 
and Rpn8, the non-ATPase regulatory  subunits with proteasom were markedly impaired in 
uPARsi cells after DOX treatment. Proteasome activator 28α (PA28α), proteasome activator 
200(PA200), Plasminogen activator inhibitor (PAI1). 
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Fig S 2.Intreraction of 19S regulatory particles to the 20S core proteasome in control 
silencing (Sico) and uPAR silencing (uPARsi) cells treated with doxorubicin.  
Proteasome purification performed by imunoprecipitation followed by western blotting. 7  
 
 
 
 
 
 
 
 
 
 
 
Fig S3. Rpn7 nuclear content in control and uPARsi cells treated with doxorubicin     
DOX -induced Rpn7 content in nuclear fraction was assessed after subcellular fractionation of 
SiCo- and uPARsi-nucleofected human VSMC. Np63 was used as loading control. The cells 
were lysed 24h after DOX treatment in SiCo and uPARsi-nucleofected human VSMC. 
 
 
                                                                                           Supplementary data                                                            
 86 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
Fig S4. Increased proteasomal activity in nucleus after Doxorubicin (DOX) 
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